Skip to main content Skip to search

Breast and Gynecologic Cancer

Publications

2024

Aragón-Sánchez, S, Sánchez-Bayona, R, López-Marín, L, Ciruelos-Gil, E, Parrilla-Rubio, L, Zaragoza-Ballester, P, Galindo-Izquierdo, A, García-Chapinal, B, Alvaro-Valiente, L, Oliver-Pérez, MR (2024).

De-escalating axillary management after neoadjuvant chemotherapy in breast cancer: The ratio of positive sentinel lymph nodes matters

SURGICAL ONCOLOGY-OXFORD. Article. 54.
[doi:10.1016/j.suronc.2024.102062]
Perez, MRO, Caso-Maestro, O, Conti-Nuño, B, Bermejo, R, Gil-Ibañez, B, Tejerizo-Garcia, A (2024).

Step by step abdominal wall closure in elective midline laparotomy

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Article.
[doi:10.1136/ijgc-2024-005500]
Bebia, V, Díaz-Feijoo, B, Tejerizo, A, Torne, A, Benito, V, Hernández, A, Gorostidi, M, Domingo, S, Bradbury, M, Luna-Guibourg, R, Gil-Moreno, A (2024).

Patterns of First Recurrence and Oncological Outcomes in Locally Advanced Cervical Cancer Patients: Does Surgical Staging Play a Role?

Cancers. Article. 16(7).
[doi:10.3390/cancers16071423]
Lorusso, D, Mouret-Reynier, MA, Harter, P, Cropet, C, Caballero, C, Wolfrum-Ristau, P, Satoh, T, Vergote, I, Parma, G, Nottrup, TJ, Lebreton, C, Fasching, PA, Pisano, C, Manso, L, Bourgeois, H, Runnebaum, I, Zamagni, C, Hardy-Bessard, AC, Schnelzer, A, Fabbro, M, Schmalfeldt, B, Berton, D, Belau, A, Lotz, JP, Gropp-Meier, M, Gladieff, L, Lück, HJ, Abadie-Lacourtoisie, S, Pujade-Lauraine, E, Ray-Coquard, I (2024).

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Article. 34(4):550-558.
[doi:10.1136/ijgc-2023-004995]
Bonilla, L, Kasherman, L, Manso, L, Madariaga, A (2024).

Mirvetuximab soravtansine: an oasis in the desert?

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Editorial Material. 34(4):478-479.
[doi:10.1136/ijgc-2024-005400]
Garcia-Lorenzo, B, Gorostiza, A, Alayo, I, Zas, SC, Baena, PC, Camina, IG, Narbaiza, BI, Mallabiabarrena, G, Ustarroz-Aguirre, I, Rigabert, A, Balzi, W, Maltoni, R, Massa, I, Lopez, IA, Lobera, SA, Esteban, M, Calleja, MF, Mediavilla, JG, Fernandez, M, Hitar, MD, Torres, MDO, Ferrandez, MCS, Sanchez, LM, Balazote, PS, Rodriguez, CV, Campone, M, Le Lann, S, Vercauter, P, Tournoy, K, Borges, M, Oliveira, AS, Soares, M, Fullaondo, A (2024).

European value-based healthcare benchmarking: moving from theory to practice

EUROPEAN JOURNAL OF PUBLIC HEALTH. Article. 34(1):44-51.
[doi:10.1093/eurpub/ckad181]

2023

El Bairi, K, Madariaga, A, Trapani, D, Al Jarroudi, O, Afqir, S (2023).

New horizons for platinum-resistant ovarian cancer: insights from the 2023 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Review. 34(5):760-772.
[doi:10.1136/ijgc-2023-004927]
Azcona, L, Heras, M, Arencibia, O, Minig, L, Marti, L, Baciu, A, Cespedes, J, Niguez, I, Gil-Ibanez, B, Diaz-Feijoo, B, Melero, LM, Sanmartin, JM, Garcia-Villayzan, J, Gomez, B, Montesinos, M, Herrero, S, Gilabert-Estelles, J, Chereguini, M, Gorostidi, M, Zapardiel, I (2023).

Prognostic factors in young women with epithelial ovarian cancer: the Young Ovarian Cancer-Care (YOC-Care) study

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Article. 34(2):285-292.
[doi:10.1136/ijgc-2023-004882]
Cedillo, S, Gari, C, Aceituno, S, Manso, L, Lleti, ACC, Bosch, PV, Casado, A, Fidalgo, AP (2023).

Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Article. 34(2):277-284.
[doi:10.1136/ijgc-2023-004786]
Bravo, V, Serrano, M, Duque, A, Ferragud, J, Coronado, PJ (2023).

Glycyrrhizinic Acid as an Antiviral and Anticancer Agent in the Treatment of Human Papillomavirus

Journal of Personalized Medicine. Review. 13(12).
[doi:10.3390/jpm13121639]
Veneziani, AC, Gonzalez-Ochoa, E, Alqaisi, H, Madariaga, A, Bhat, G, Rouzbahman, M, Sneha, S, Oza, AM (2023).

Heterogeneity and treatment landscape of ovarian carcinoma

NATURE REVIEWS CLINICAL ONCOLOGY. Review. 20(12):820-842.
[doi:10.1038/s41571-023-00819-1]
Gambacorta N, Gasperi V, Guzzo T, Di Leva FS, Ciriaco F, Sánchez C, Tullio V, Rozzi D, Marinelli L, Topai A, Nicolotti O, Maccarrone M (2023).

Exploring the 1,3-benzoxazine chemotype for cannabinoid receptor 2 as a promising anti-cancer therapeutic.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. Article. 259:115647-115647.
[doi:10.1016/j.ejmech.2023.115647]
Cabrera, S, Gómez-Hidalgo, NR, García-Pineda, V, Bebia, V, Fernández-González, S, Alonso, P, Rodríguez-Gómez, T, Fusté, P, Gracia-Segovia, M, Lorenzo, C, Chacon, E, Rivas, FR, Arencibia, O, Edo, MM, Fidalgo, S, Sanchis, J, Padilla-Iserte, P, Pantoja-Garrido, M, Martínez, S, Peiró, R, Escayola, C, Oliver-Pérez, MR, Aghababyan, C, Tauste, C, Morales, S, Torrent, A, Utrilla-Layna, J, Fargas, F, Calvo, A, de Pace, LA, Gil-Moreno, A (2023).

ASO Visual Abstract: Accuracy and Survival Outcomes After National Implementation of Sentinel Lymph Node Biopsy in Early-Stage Endometrial Cancer

ANNALS OF SURGICAL ONCOLOGY. Editorial Material. 30(12):7669-7670.
[doi:10.1245/s10434-023-14167-y]
Cabrera, S, Gómez-Hidalgo, NR, García-Pineda, V, Bebia, V, Fernández-González, S, Alonso, P, Rodríguez-Gómez, T, Fusté, P, Gracia-Segovia, M, Lorenzo, C, Chacon, E, Rivas, FR, Arencibia, O, Edo, MM, Fidalgo, S, Sanchis, J, Padilla-Iserte, P, Pantoja-Garrido, M, Martínez, S, Peiró, R, Escayola, C, Oliver-Pérez, MR, Aghababyan, C, Tauste, C, Morales, S, Torrent, A, Utrilla-Layna, J, Fargas, F, Calvo, A, de Pace, LA, Gil-Moreno, A (2023).

Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer

ANNALS OF SURGICAL ONCOLOGY. Article. 30(12):7653-7662.
[doi:10.1245/s10434-023-14065-3]
Antolín Novoa S, Escrivá-de-Romaní S, Tolosa Ortega P, Oliva Fernández L, López López R, López González A, de la Morena Barrio P, Echavarria Díaz-Guardamino I, Alés Martinez JE, Garate Z, González-Cortijo L (2023).

Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study).

Cancer Treatment and Research Communications. Article. 37:100772-100772.
[doi:10.1016/j.ctarc.2023.100772]
de la Pena, FA, Novoa, SA, Gregori, JG, Cortijo, LG, Carrasco, FH, Martinez, MTM, Estevez, CM, Stradella, A, Losada, MJV, Ciruelos, E (2023).

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (vol 25, pg 2647, 2023)

CLINICAL & TRANSLATIONAL ONCOLOGY. Correction.
[doi:10.1007/s12094-023-03334-y]
Rugo, HS, Bardia, A, Marme, F, Cortes, J, Schmid, P, Loirat, D, Tredan, O, Ciruelos, E, Dalenc, F, Pardo, PG, Jhaveri, KL, Delaney, R, Valdez, T, Wang, H, Motwani, M, Yoon, OK, Verret, W, Tolaney, SM (2023).

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02) a randomised, open-label, multicentre, phase 3 trial

LANCET. Article. 402(10411):1423-1433.
[doi:10.1016/S0140-6736(23)01245]
Bueno, MJ, Mouron, S, Caleiras, E, Martínez, M, Manso, L, Colomer, R, Quintela-Fandino, M (2023).

Distribution of PD-L1, TROP2 and HER2-"lowness" in early triple-negative breast cancer: an opportunity for treatment de-escalation

CLINICAL & TRANSLATIONAL ONCOLOGY. Article.
[doi:10.1007/s12094-023-03329-9]
Pascual, J, Gil-Gil, M, Proszek, P, Zielinski, C, Reay, A, Ruiz-Borrego, M, Cutts, R, Gil, EMC, Feber, A, Muñoz-Mateu, M, Swift, C, Bermejo, B, Herranz, J, Vila, MM, Antón, A, Kahan, Z, Csöszi, T, Liu, Y, Fernandez-Garcia, D, Garcia-Murillas, I, Hubank, M, Turner, NC, Martín, M (2023).

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

CLINICAL CANCER RESEARCH. Article. 29(20):4166-4177.
[doi:10.1158/1078-0432.CCR-23-0956]
Terán, S, Alva, M, Tolosa, P, Rey-Cardenas, M, Madariaga, A, Lema, L, Ruano, Y, Manso, L, Ciruelos, E, Sánchez-Bayona, R (2023).

Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer

Breast. Article. 71:42-46.
[doi:10.1016/j.breast.2023.07.009]
Rey-Cárdenas, M, Parrilla-Rubio, L, Manso, L, Sanchez-Bayona, R, Alvarez-Conejo, C, Madariaga, A (2023).

Digging into phenotype change in mismatch repair deficient endometrial carcinoma and treatment with immune checkpoint inhibition, a case report

Gynecologic Oncology Reports. Editorial Material. 49.
[doi:10.1016/j.gore.2023.101278]
Gil-Ibanez, B, Tejerizo-Garcia, A, Oliver, MR, Madariaga, A, Jimenez, MM, Garcia, AG, Lopez-Gonzalez, G (2023).

Side effects screening and early intervention to impact in quality of life of patients with gynecological cancers (HALIS study)

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Article. 33(10):1645-1648.
[doi:10.1136/ijgc-2023-004802]
Wang, XQ, Danenberg, E, Huang, CS, Egle, D, Callari, M, Bermejo, B, Dugo, M, Zamagni, C, Thill, M, Anton, A, Zambelli, S, Russo, S, Ciruelos, EM, Greil, R, Györffy, B, Semiglazov, V, Colleoni, M, Kelly, CM, Mariani, G, Del Mastro, L, Biasi, O, Seitz, RS, Valagussa, P, Viale, G, Gianni, L, Bianchini, G, Ali, HR (2023).

Spatial predictors of immunotherapy response in triple-negative breast cancer

Nature. Article. 621(7980):868.
[doi:10.1038/s41586-023-06498-3]
Gil-Ibanez, B, Davies-Oliveira, J, Lopez, G, Díaz-Feijoo, B, Tejerizo-Garcia, A, Sehouli, J (2023).

Impact of gynecological cancers on health-related quality of life: historical context, measurement instruments, and current knowledge

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Review. 33(11):1800-1806.
[doi:10.1136/ijgc-2023-004804]
Quintana-Bertó, R, Padilla-Iserte, P, Lago, V, Tauste, C, Díaz-Feijoo, B, Cabrera, S, Oliver-Pérez, R, Coronado, PJ, Martín-Salamanca, MB, Pantoja-Garrido, M, Marcos-Sanmartin, J, Cazorla, E, Lorenzo, C, Rodríguez-Hernández, JR, Roldán-Rivas, F, Gilabert-Estellés, J, Muruzábal, JC, Cañada, A, Domingo, S (2023).

Endometrial cancer: predictors and oncological safety of tumor tissue manipulation

CLINICAL & TRANSLATIONAL ONCOLOGY. Article.
[doi:10.1007/s12094-023-03310-6]
de la Peña, FA, Novoa, SA, Gregori, JG, Cortijo, LG, Carrasco, FH, Martínez, MTM, Estévez, CM, Stradella, A, Losada, MJV, Ciruelos, E (2023).

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 25(9):2647-2664.
[doi:10.1007/s12094-023-03215-4]
Martínez-Illescas, NG, Leal, S, González, P, Graña-Castro, O, Muñoz-Oliveira, JJ, Cortés-Peña, A, Gómez-Gil, M, Vega, Z, Neva, V, Romero, A, Quintela-Fandino, M, Ciruelos, E, Sanz, C, Aragón, S, Sotolongo, L, Jiménez, S, Caleiras, E, Mulero, F, Sánchez, C, Malumbres, M, Salazar-Roa, M (2023).

miR-203 drives breast cancer cell differentiation

BREAST CANCER RESEARCH. Article. 25(1).
[doi:10.1186/s13058-023-01690-9]
Lahera, A, Vela-Martín, L, López-Nieva, P, Salgado, RN, Rodríguez-Perales, S, Torres-Ruiz, R, López-Lorenzo, JL, Cornago, J, Llamas, P, Fernández-Navarro, P, Sánchez-Domínguez, R, Segovia, JC, Sastre, I, Cobos-Fernández, MA, Menéndez, P, Santos, J, Fernández-Piqueras, J, Villa-Morales, M (2023).

Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL

BRITISH JOURNAL OF HAEMATOLOGY. Letter. 202(3):693-698.
[doi:10.1111/bjh.18901]
Yubero, A, Estévez, P, Barquín, A, Sánchez, L, Santaballa, A, Pajares, B, Reche, P, Salvador, C, Manso, L, Márquez, R, González-Martín, A (2023).

Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program

Gynecologic Oncology Reports. Article. 48.
[doi:10.1016/j.gore.2023.101211]
Oliveira, M, Falato, C, Cejalvo, JM, Vila, MM, Tolosa, P, Salvador-Bo, FJ, Cruz, J, Arumi, M, Luna, AM, Guerra, JA, Vidal, M, Martínez-Sáez, O, Paré, L, González-Farré, B, Sanfeliu, E, Ciruelos, E, Espinosa-Bravo, M, Pernas, S, Izarzugaza, Y, Esker, S, Fan, PD, Parul, P, Santhanagopal, A, Sellami, D, Villacampa, G, Ferrero-Cafiero, JM, Pascual, T, Prat, A (2023).

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of- opportunity SOLTI TOT-HER3 pre-operative study

ANNALS OF ONCOLOGY. Article. 34(8):670-680.
[doi:10.1016/j.annonc.2023.05.004]
Meric-Bernstam, F, Makker, V, Oaknin, A, Oh, D, Banerjee, SN, Martin, AG, Jung, KH, Lugowska, IA, Manso, L, Manzano, A, Melichar, B, Siena, S, Stroyakovskiy, D, Anoka, C, Ma, Y, Puvvada, SD, Lee, JY (2023).

Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.

JOURNAL OF CLINICAL ONCOLOGY. Article. 41(17_SUPPL):3000-3000.
[doi:10.1200/JCO.2023.41.17_suppl.LBA3000]
Schettini, F, Martínez-Sáez, O, Falato, C, De Santo, I, Conte, B, Garcia-Fructuoso, I, Gomez-Bravo, R, Seguí, E, Chic, N, Brasó-Maristany, F, Paré, L, Vidal, M, Adamo, B, Muñoz, M, Pascual, T, Ciruelos, E, Perou, CM, Carey, LA, Prat, A (2023).

Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis

Esmo Open. Review. 8(3).
[doi:10.1016/j.esmoop.2023.101214]
Perez-Fidalgo, JA, Guerra, E, García, Y, Iglesias, M, Hernández-Sosa, M, Estevez-García, P, Sánchez, LM, Santaballa, A, Oaknin, A, Redondo, A, Rubio, MJ, González-Martín, A (2023).

Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Article. 33(6):929-936.
[doi:10.1136/ijgc-2022-004028]
Minig, L, Segovia, MG, Arencibia, O, Zorrero, C, Marti, L, Pineda, VG, Cespedes, J, Niguez, I, Gil-Ibanez, B, Diaz-Feijoo, B, Fidalgo, S, Valencia, I, Alonso-Gutierrez, T, Gonzalez, L, Veiga-Fernandez, A, Chacon, E, Negredo, I, Sutil, LA, Gorostidi, M, Zapardiel, I (2023).

Oncological outcomes among young women with non-epithelial ovarian cancer: the YOC-Care study (Young Ovarian Cancer - Care)

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Article. 33(6):915-921.
[doi:10.1136/ijgc-2022-004162]
Villa-Morales, M, Pérez-Gómez, L, Pérez-Gómez, E, López-Nieva, P, Fernández-Navarro, P, Santos, J (2023).

Identification of NRF2 Activation as a Prognostic Biomarker in T-Cell Acute Lymphoblastic Leukaemia

International Journal Of Molecular Sciences. Article. 24(12).
[doi:10.3390/ijms241210350]
Tundidor, I, Seijo-Vila, M, Blasco-Benito, S, Rubert-Hernández, M, Adámez, S, Andradas, C, Manzano, S, Alvarez-López, I, Sarasqueta, C, Villa-Morales, M, González-Lois, C, Ramírez-Medina, E, Almoguera, B, Sánchez-López, AJ, Bindila, L, Hamann, S, Arnold, N, Röcken, C, Heras-Murillo, I, Sancho, D, Moreno-Bueno, G, Caffarel, MM, Guzmán, M, Sánchez, C, Pérez-Gómez, E (2023).

Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer

NATURE COMMUNICATIONS. Article. 14(1).
[doi:10.1038/s41467-023-38750-9]
Sánchez-Cánovas, M, Jimenez-Fonseca, P, Garay, DF, Solís, MC, Elía, DC, Salvans, EC, Vacas, ID, Sánchez, DG, Montés, AF, Giménez, RM, de Tejada, MBG, Arrula, VA, López, SS, Candelera, RO, Cendra, CS, de la Peña, MJ, Muñoz, DM, Sarmiento, MO, de Castro, EM, Escobar, IG, Vidal, AB, Moran, LO, Martín, AJM, Bayona, RS, Ortiz, MJM, de la Peña, FA, Vicente, V, Carmona-Bayonas, A (2023).

Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

PLOS ONE. Article. 18(5).
[doi:10.1371/journal.pone.0266305]
Oliver-Perez, MR, Padilla-Iserte, P, Arencibia-Sanchez, O, Martin-Arriscado, C, Muruzabal, JC, Diaz-Feijóo, B, Cabrera, S, Coronado, P, Martín-Salamanca, MB, Pantoja-Garrido, M, Marcos-Sanmartin, J, Cabezas-López, E, Lorenzo, C, Beric, D, Rodriguez-Hernandez, JR, Roldan-Rivas, F, Gilabert-Estelles, J, Sanchez, L, Laseca-Modrego, M, Tauste-Rubio, C, Gil-Ibañez, B, Tejerizo-Garcia, A (2023).

Lymphovascular Space Invasion in Early-Stage Endometrial Cancer (LySEC): Patterns of Recurrence and Predictors. A Multicentre Retrospective Cohort Study of the Spain Gynecologic Oncology Group

Cancers. Article. 15(9).
[doi:10.3390/cancers15092612]
Oliver, MD, Betoret, RM (2023).

Treatment of primary and recurrent vulvar and vaginal cancer including rare vulvo-vaginal malignancies

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Editorial Material. 33:19-19.
Aguilera-Buenosvinos, I, Martínez-González, MA, Zazpe, I, Romanos-Nanclares, A, Sánchez-Bayona, R, Toledo, E (2023).

Associations between overall, healthful, and unhealthful low-fat dietary patterns and breast cancer risk in a Mediterranean cohort: The SUN project

NUTRITION. Article. 109.
[doi:10.1016/j.nut.2022.111967]
Olivera-Salguero, R, Seguí, E, Cejalvo, JM, Oliveira, M, Tolosa, P, Vidal, M, Malumbres, M, Gavilá, J, Saura, C, Pernas, S, López, R, Margelí, M, Balmaña, J, Muñoz, M, Blancas, I, Boni, V, Ciruelos, E, Galve, E, Perelló, A, Sánchez-Bayona, R, de la Cruz, S, de la Hoya, M, Galván, P, Sanfeliu, E, Gonzalez-Farre, B, Sirenko, V, Blanch-Torras, A, Canes, J, Masanas, H, Olmos, R, Forns, M, Prat, A, Casas, A, Pascual, T (2023).

HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

Frontiers in oncology. Article. 13.
[doi:10.3389/fonc.2023.1151496]
Costas-Insua, C, Seijo-Vila, M, Blázquez, C, Blasco-Benito, S, Rodríguez-Baena, FJ, Marsicano, G, Pérez-Gómez, E, Sánchez, C, Sánchez-Laorden, B, Guzmán, M (2023).

Neuronal Cannabinoid CB1 Receptors Suppress the Growth of Melanoma Brain Metastases by Inhibiting Glutamatergic Signalling

Cancers. Article. 15(9).
[doi:10.3390/cancers15092439]
Guerrero-Zotano, A, Belli, S, Zielinski, C, Gil-Gil, M, Fernandez-Serra, A, Ruiz-Borrego, M, Gil, EMC, Pascual, J, Muñoz-Mateu, M, Bermejo, B, Vila, MM, Antón, A, Murillo, L, Nissenbaum, B, Liu, Y, Herranz, J, Fernández-García, D, Caballero, R, López-Guerrero, JA, Bianco, R, Formisano, L, Turner, N, Martín, M (2023).

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2-Metastatic Breast Cancer

CLINICAL CANCER RESEARCH. Article. 29(8):1557-1568.
[doi:10.1158/1078-0432.CCR-22-2206]
Luen, SJ, Viale, G, Nik-Zainal, S, Savas, P, Kammler, R, Dell'Orto, P, Biasi, O, Degasperi, A, Brown, LC, Láng, I, MacGrogan, G, Tondini, C, Bellet, M, Villa, F, Bernardo, A, Ciruelos, E, Karlsson, P, Neven, P, Climent, M, Müller, B, Jochum, W, Bonnefoi, H, Martino, S, Davidson, NE, Geyer, C, Chia, SK, Ingle, JN, Coleman, R, Solbach, C, Thürlimann, B, Colleoni, M, Coates, AS, Goldhirsch, A, Fleming, GF, Francis, PA, Speed, TP, Regan, MM, Loi, S (2023).

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

ANNALS OF ONCOLOGY. Article. 34(4):397-409.
[doi:10.1016/j.annonc.2023.01.009]
Sarkis, R, Burri, O, Royer-Chardon, C, Schyrr, F, Blum, S, Costanza, M, Cherix, S, Piazzon, N, Barcena, C, Bisig, B, Nardi, V, Sarro, R, Ambrosini, G, Weigert, M, Spertini, O, Blum, S, Deplancke, B, Seitz, A, de Leval, L, Naveiras, O (2023).

MarrowQuant 2.0: A Digital Pathology Workflow Assisting Bone Marrow Evaluation in Experimental and Clinical Hematology

MODERN PATHOLOGY. Article. 36(4).
[doi:10.1016/j.modpat.2022.100088]
Jimeno, R, Mouron, S, Salgado, R, Loi, S, Perez-Mies, B, Sanchez-Bayona, R, Manso, L, Martinez, M, Garrido-Garcia, A, Serrano-Pardo, R, Colomer, R, Quintela-Fandino, M (2023).

Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 25(4):1124-1131.
[doi:10.1007/s12094-022-03006-3]
Madariaga, A, Garg, S, Tchrakian, N, Dhani, NC, Jimenez, W, Welch, S, MacKay, H, Ethier, JL, Gilbert, L, Li, X, Rodriguez, A, Chan, LCY, Bowering, V, Clarke, B, Zhang, T, King, I, Downs, G, Stockley, T, Wang, LS, Udagani, S, Oza, AM, Lheureux, S (2023).

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma

NATURE COMMUNICATIONS. Article. 14(1).
[doi:10.1038/s41467-023-37084-w]
Madariaga A, Sanchez-Bayona R, Herrera FG, Ramirez PT, González Martín A (2023).

Outcomes and endpoints of relevance in gynecologic cancer clinical trials.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Review. 33(3):323-332.
[doi:10.1136/ijgc-2022-003727]
Madariaga, A, Coleman, RL, González Martín A (2023).

Novel therapies leading to a new landscape in gynecologic tumors.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Editorial Material. 33(3):321-322.
[doi:10.1136/ijgc-2023-004318]
Jiménez-Ubieto, A, Poza, M, Martin-Muñoz, A, Ruiz-Heredia, Y, Dorado, S, Figaredo, G, Rosa-Rosa, JM, Rodriguez, A, Barcena, C, Navamuel, LP, Carrillo, J, Sanchez, R, Rufian, L, Juárez, A, Rodriguez, M, Wang, C, de Toledo, P, Grande, C, Mollejo, M, Casado, LF, Calbacho, M, Baumann, T, Rapado, I, Gallardo, M, Sarandeses, P, Ayala, R, Martínez-López, J, Barrio, S (2023).

Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT

LEUKEMIA. Article. 37(3):659-669.
[doi:10.1038/s41375-022-01803-x]
Prat, A, Brasó-Maristany, F, Martínez-Sáez, O, Sanfeliu, E, Xia, YL, Bellet, M, Galván, P, Martínez, D, Pascual, T, Marín-Aguilera, M, Rodríguez, A, Chic, N, Adamo, B, Paré, L, Vidal, M, Margelí, M, Ballana, E, Gómez-Rey, M, Oliveira, M, Felip, E, Matito, J, Sánchez-Bayona, R, Suñol, A, Saura, C, Ciruelos, E, Tolosa, P, Muñoz, M, González-Farré, B, Villagrasa, P, Parker, JS, Perou, CM, Vivancos, A (2023).

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

NATURE COMMUNICATIONS. Article. 14(1).
[doi:10.1038/s41467-023-36801-9]
Hogeboom, A, Bárcena, C, Parrilla-Rubio, L, Revilla, E, Ruano, Y, Gallego-Gutiérrez, I, Martínez-López, M (2023).

A Case of COL1A1-PDGFB Fusion Uterine Sarcoma

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY. Article. 42(2):147-150.
[doi:10.1097/PGP.0000000000000875]
Mouron, S, Bueno, MJ, Muñoz, M, Torres, R, Rodríguez, S, Apala, JV, Silva, J, Sánchez-Bayona, R, Manso, L, Guerra, J, Rodriguez-Lajusticia, L, Malon, D, Malumbres, M, Quintela-Fandino, M (2023).

p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor-positive breast cancer

Jnci Cancer Spectrum. Article. 7(2).
[doi:10.1093/jncics/pkad014]
Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winer EP, Ruepp B, Loi S, Coates AS, Gelber RD, Goldhirsch A, Regan MM, Francis PA (2023).

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.

JOURNAL OF CLINICAL ONCOLOGY. Article. 41(7):1376-1382.
[doi:10.1200/JCO.22.01064]
Cueva, JF, Palacio, I, Churruca, C, Herrero, A, Pardo, B, Constenla, M, Santaballa, A, Manso, L, Estévez, P, Maximiano, C, Legerén, M, Marquina, G, de Juan, A, Quindós, M, Sánchez, L, Barquin, A, Fernández, I, Martín, C, Juárez, A, Martín, T, García, Y, Yubero, A, Gallego, A, Martínez Bueno A, Guerra, E, González-Martín, A (2023).

Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.

EUROPEAN JOURNAL OF CANCER. Article. 182:3-14.
[doi:10.1016/j.ejca.2022.12.023]
Chang-Azancot L, Abizanda P, Gijón M, Kenig N, Campello M, Juez J, Talaya A, Gómez-Bajo G, Montón J, Sánchez-Bayona R (2023).

Age and Breast Reconstruction.

AESTHETIC PLASTIC SURGERY. Article. 47(1):63-72.
[doi:10.1007/s00266-022-03024-0]
Oliver, MD, Betoret, RM (2023).

Treatment of primary and recurrent vulvar and vaginal cancer including rare vulvo-vaginal malignancies

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Editorial Material. 33(SUPPL_1):19-19.
de la Torre, P, Pérez-Lorenzo, MJ, Alcázar-Garrido, A, Collado, J, Martínez-López, M, Forcén, L, Masero-Casasola, AR, García, A, Gutiérrez-Vélez, MC, Medina-Polo, J, Muñoz, E, Flores, AI (2023).

Perinatal mesenchymal stromal cells of the human decidua restore continence in rats with stress urinary incontinence induced by simulated birth trauma and regulate senescence of fibroblasts from women with stress urinary incontinence.

Frontiers In Cell And Developmental Biology. Article. 10:1033080-1033080.
[doi:10.3389/fcell.2022.1033080]
Mair, MJ, Cardone, C, Connolly, L, Kfoury, M, Lambertini, M, Lim, J, Mariamidze, E, Matikas, A, Pihlak, R, Punie, K, Oing, C, Sanchez-Bayona, R, Sobczuk, P, Zhu, HC, Berghoff, AS, Amaral, T (2023).

Career and Professional Development for Young Oncologists

ONCOLOGY RESEARCH AND TREATMENT. Article. 46(3):67-71.
[doi:10.1159/000528541]

2022

Carretero-Gonzalez, A, Hergueta-Redondo, M, Sanchez-Redondo, S, Ximenez-Embun, P, Sanchez, LM, Gil, EC, Castellano, D, de Velasco, G, Peinado, H (2022).

Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis

OncoImmunology. Article. 11(1):2067944-2067944.
[doi:10.1080/2162402X.2022.2067944]
Pinto-Díez C, Ferreras-Martín R, Carrión-Marchante R, Klett-Mingo JI, García-Hernández M, Pérez-Morgado MI, Sacristán S, Barragán M, Seijo-Vila M, Tundidor I, Blasco-Benito S, Pérez-Gómez E, Gómez-Pinto I, Sánchez C, González C, González VM, Martín ME (2022).

An optimized MNK1b aptamer, apMNKQ2, and its potential use as a therapeutic agent in breast cancer.

MOLECULAR THERAPY NUCLEIC ACIDS. Article. 30:553-568.
[doi:10.1016/j.omtn.2022.11.009]
Mouron S, Bueno MJ, Lluch A, Manso L, Calvo I, Cortes J, Garcia-Saenz JA, Gil-Gil M, Martinez-Janez N, Apala JV, Caleiras E, Ximénez-Embún P, Muñoz J, Gonzalez-Cortijo L, Murillo R, Sánchez-Bayona R, Cejalvo JM, Gómez-López G, Fustero-Torre C, Sabroso-Lasa S, Malats N, Martinez M, Moreno A, Megias D, Malumbres M, Colomer R, Quintela-Fandino M (2022).

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A.

NATURE COMMUNICATIONS. Article. 13(1):7529-7529.
[doi:10.1038/s41467-022-35065-z]
Corona SP, Giudici F, Jerusalem G, Ciruelos E, Strina C, Sirico M, Bernocchi O, Milani M, Dester M, Ziglioli N, Barbieri G, Cervoni V, Montemurro F, Generali D (2022).

Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.

Oncotarget. Correction. 13:1307-1307.
[doi:10.18632/oncotarget.28317]
Marín-Rubio JL, Vela-Martín L, Gudgeon J, Pérez-Gómez E, Sidgwick FR, Trost M, Cunningham DL, Santos J, Fernández-Piqueras J, Villa-Morales M (2022).

A Dual Role for FADD in Human Precursor T-Cell Neoplasms.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Article. 23(23).
[doi:10.3390/ijms232315157]
Bofill, JS, Anton, FM, Sanchez, CAR, Calvo, EG, Melia, CH, Gil, EMC, Vidal, M, Jimenez-Rodriguez, B, Merino, LD, Janez, NM, Vazquez, RV, Salas, RD, Torres, AA, Lopez, IMA, Gregori, JG, Garcia, VQ, Rubio, EV, De la Haba-Rodriguez, J, Gonzalez-Santiago, S, Fernandez, ND, Molins, AB, De Ibarguen, BCS, Mingorance, JID, Ezquerra, MB, De Casa, S, Gimeno, A, Martin, M (2022).

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

Breast. Article. 66:77-84.
[doi:10.1016/j.breast.2022.09.006]
Quintana-Berto, R, Padilla-Iserte, P, Gil-Moreno, A, Oliver-Perez, R, Coronado, PJ, Martin-Salamanca, MB, Pantoja-Garrido, M, Lorenzo, C, Beric, D, Gilabert-Estelles, J, Sanchez, L, Roldan-Rivas, F, Diaz-Feijoo, B, Rodriguez-Hernandez, JR, Marcos-Sanmartin, J, Muruzabal, JC, Canada, A, Domingo, S (2022).

Preoperative sampling in endometrial cancer: evaluation of the histopathological agreement with definitive surgical specimen

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 24(12):2388-2394.
[doi:10.1007/s12094-022-02893-w]
Yubero, A, Barquin, A, Estevez, P, Pajares, B, Sanchez, L, Reche, P, Alarcon, J, Calzas, J, Gaba, L, Fuentes, J, Santaballa, A, Salvador, C, Manso, L, Herrero, A, Taus, A, Marquez, R, Madani, J, Merino, M, Marquina, G, Casado, V, Constenla, M, Gutierrez, M, Dosil, A, Gonzalez-Martin, A (2022).

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study

BMC CANCER. Article. 22(1):1150-1150.
[doi:10.1186/s12885-022-10191-5]
Munoz-Hernando, L, Oliver-Perez, R, Bravo-Violeta, V, Olloqui, A, Parte-Izquierdo, B, Almansa-Gonzalez, C, Bermejo-Martinez, R, Miguel, ABBD, Diez, A, Seoane-Ruiz, JM, Parrilla-Rubio, L, Tejerizo-Garcia, A (2022).

Prevalence of Anal High-Risk Human Papilloma Virus Infection and Abnormal Anal Cytology among Women Living with HIV

Journal of Personalized Medicine. Article. 12(11).
[doi:10.3390/jpm12111778]
López-Marín L, Olloqui A, Villalba A, Puente JM, Galindo A (2022).

A case of intestinal schwannoma initially suspected by transvaginal ultrasound.

Radiology Case Reports. Case Reports. 17(11):4362-4364.
[doi:10.1016/j.radcr.2022.08.028]
Errazquin R, Page A, Suñol A, Segrelles C, Carrasco E, Peral J, Garrido-Aranda A, Del Marro S, Ortiz J, Lorz C, Minguillon J, Surralles J, Belendez C, Alvarez M, Balmaña J, Bravo A, Ramirez A, Garcia-Escudero R (2022).

Development of a mouse model for spontaneous oral squamous cell carcinoma in Fanconi anemia.

ORAL ONCOLOGY. Article. 134:106184-106184.
[doi:10.1016/j.oraloncology.2022.106184]
Madariaga, A, Mitchell, SA, Pittman, T, Wang, LS, Bowering, V, Kavak, N, Quintos, J, Chang, K, Ramsahai, J, Karakasis, K, Welch, SA, Dhani, NC, Lheureux, S, Oza, AM (2022).

Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma.

GYNECOLOGIC ONCOLOGY. Article. 167(2):226-233.
[doi:10.1016/j.ygyno.2022.08.006]
Rugo, HS, Bardia, A, Marme, F, Cortes, J, Schmid, P, Loirat, D, Tredan, O, Ciruelos, E, Dalenc, F, Pardo, PG, Jhaveri, KL, Delaney, R, Fu, O, Lin, L, Verret, W, Tolaney, SM (2022).

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

JOURNAL OF CLINICAL ONCOLOGY. Article. 40(29):3365.
[doi:10.1200/JCO.22.01002]
Bartolome, A, Villalain, C, Bermejo, R, Bolivar, AB, Castillo, LP, Galindo, A, Tejerizo, A (2022).

Spanish Translation, Transcultural Adaptation, Validation and Clinical Applicability of Female Genital-Self Image Scale (FGSIS)

Sexual Medicine. Article. 10(5):100558-100558.
[doi:10.1016/j.esxm.2022.100558]
Villacampa, G, Falato, C, Pare, L, Hernando, C, Arumi, M, Saura, C, Gomez, G, Munoz, M, Gil-Gil, M, Izarzugaza, Y, Ferrer, N, Najera-Zuloaga, J, Montano, A, Ciruelos, E, Gonzalez-Santiago, S, Villagrasa, P, Gavila, J, Prat, A, Pascual, T (2022).

Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial

EUROPEAN JOURNAL OF CANCER. Article. 174:232-242.
[doi:10.1016/j.ejca.2022.07.028]
Madariaga, A, Lau, J, Dzierzanowski, T, Ghoshal, A, Larkin, P, Sobocki, J, Dickman, A, Furness, K, Fazelzad, R, Crawford, GB, Lheureux, S (2022).

Response to Cleary et al. re MASCC evidence-based recommendations for the management of malignant bowel obstruction

SUPPORTIVE CARE IN CANCER. Letter. 30(10):7825-7826.
[doi:10.1007/s00520-022-07304-y]
Lago, V, Segarra-Vidal, B, Cappucio, S, Angeles, MA, Fotopoulou, C, Muallem, MZ, Manzanedo, I, Iglesias JLS, Chacon, E, Padilla-Iserte, P, Fagotti, A, Ferron, G, Kluge, L, Vargiu, V, Del, M, Scambia, G, Minig, L, Tejerizo, A, Segovia, MG, Cascales-Campos, PA, Hervás D, Domingo S (2022).

OVA-LEAK: Prognostic score for colo-rectal anastomotic leakage in patients undergoing ovarian cancer surgery.

GYNECOLOGIC ONCOLOGY. Article. 167(1):22-27.
[doi:10.1016/j.ygyno.2022.08.004]
Aragon-Sanchez, S, Ciruelos-Gil, E, Lopez-Marin, L, Galindo, A, Tabuenca-Mateos, MJ, Jimenez-Arranz, S, Colmenero-Hernandez, M, Oliver-Perez, MR (2022).

Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer

SURGICAL ONCOLOGY-OXFORD. Article. 44:101823-101823.
[doi:10.1016/j.suronc.2022.101823]
Aragon-Sanchez, S, Oliver-Perez, MR, Madariaga, A, Tabuenca, MJ, Martinez, M, Galindo, A, Arroyo, ML, Gallego, M, Blanco, M, Ciruelos-Gil, EM (2022).

Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes

Breast Journal. Article. 2022:1507881-1507881.
[doi:10.1155/2022/1507881]
Rodríguez M, Alonso-Alonso R, Fernández-Miranda I, Mondéjar R, Cereceda L, Tráscasa Á, Antonio-Da Conceiçao A, Borregón J, Gato L, Tomás-Roca L, Bárcena C, Iglesias B, Climent F, González-Barca E, Camacho FI, Mayordomo É, Olmedilla G, Gómez-Prieto P, Castro Y, Serrano-López J, Sánchez-García J, Montes-Moreno S, García-Cosío M, Martín-Acosta P, García JF, Planelles M, Quero C, Provencio M, Mahíllo-Fernández I, Rodríguez-Pinilla SM, Derenzini E, Pileri S, Sánchez-Beato M, Córdoba R, Piris MA (2022).

An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.

Ejhaem. Article. 3(3):722-733.
[doi:10.1002/jha2.457]
Martinez, M, Jimenez, S, Guzman, F, Fernandez, M, Arizaga, E, Sanz, C (2022).

Evaluation of Axillary Lymph Node Marking with Magseed (R) before and after Neoadjuvant Systemic Therapy in Breast Cancer Patients: MAGNET Study

Breast Journal. Article. 2022:6111907-6111907.
[doi:10.1155/2022/6111907]
Gerratana L, Pierga JY, Reuben JM, Davis AA, Wehbe FH, Dirix L, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, Bonotto M, Fernandez de Lascoiti A, De Mattos-Arruda L, Ignatiadis M, Sandri MT, Generali D, De Angelis C, Dawson SJ, Janni W, Carañana V, Riethdorf S, Solomayer EF, Puglisi F, Giuliano M, Pantel K, Bidard FC, Cristofanilli M (2022).

Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.

ONCOLOGIST. Article. 27(7):561-570.
[doi:10.1093/oncolo/oyac045]
Méndez-Líter JA, Pozo-Rodríguez A, Madruga E, Rubert M, Santana AG, de Eugenio LI, Sánchez C, Martínez A, Prieto A, Martínez MJ (2022).

Glycosylation of Epigallocatechin Gallate by Engineered Glycoside Hydrolases from Talaromyces amestolkiae: Potential Antiproliferative and Neuroprotective Effect of These Molecules.

Antioxidants. Article. 11(7).
[doi:10.3390/antiox11071325]
Sanchez-Bayona, R, Bes-Rastrollo, M, Fernandez-Lazaro, CI, Bastyr, M, Madariaga, A, Pons, JJ, Martinez-Gonzalez, MA, Toledo, E (2022).

Vitamin D and Risk of Obesity-Related Cancers: Results from the SUN ('Seguimiento Universidad de Navarra') Project

Nutrients. Article. 14(13).
[doi:10.3390/nu14132561]
Sánchez-Bayona R, Garcia Del Barrio MA, Alegre E, Fernandez-Hidalgo OA, Eslava MS (2022).

Trastuzumab and thyroid dysfunction: An association to be aware of.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS. Case Reports. 18(4):1183-1185.
[doi:10.4103/jcrt.JCRT_66_19]
Llueca A, Ibañez MV, Torne A, Gil-Moreno A, Martin-Jimenez A, Diaz-Feijoo B, Serra A, Climent MT, Gil-Ibañez B (2022).

Fertility-Sparing Surgery versus Radical Hysterectomy in Early Cervical Cancer: A Propensity Score Matching Analysis and Noninferiority Study.

Journal of Personalized Medicine. Article. 12(7).
[doi:10.3390/jpm12071081]
Madariaga, A, Lau, J, Ghoshal, A, Dzierzanowski, T, Larkin, P, Sobocki, J, Dickman, A, Furness, K, Fazelzad, R, Crawford, GB, Lheureux, S (2022).

MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer

SUPPORTIVE CARE IN CANCER. Article. 30(6):4711-4728.
[doi:10.1007/s00520-022-06889-8]
Sanchez-Baltasar R, Garcia-Torralba A, Nieto-Romero V, Page A, Molinos-Vicente A, López-Manzaneda S, Ojeda-Pérez I, Ramirez A, Navarro M, Segovia JC, García-Bravo M (2022).

Efficient and Fast Generation of Relevant Disease Mouse Models by In Vitro and In Vivo Gene Editing of Zygotes.

CRISPR Journal. Article. 5(3):422-434.
[doi:10.1089/crispr.2022.0013]
Martin, M, Zielinski, C, Ruiz-Borrego, M, Carrasco, E, Ciruelos, EM, Munoz, M, Bermejo, B, Margeli, M, Csoszi, T, Anton, A, Turner, N, Casas, MI, Morales, S, Alba, E, Calvo, L, De La Haba-Rodriguez, J, Ramos, M, Murillo, L, Santaballa, A, Alonso-Romero, JL, Sanchez-Rovira, P, Corsaro, M, Huang, X, Thallinger, C, Kahan, Z, Gil-Gil, M (2022).

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

EUROPEAN JOURNAL OF CANCER. Article. 168:12-24.
[doi:10.1016/j.ejca.2022.03.006]
Marastoni S, Madariaga A, Pesic A, Nair SN, Li ZJ, Shalev Z, Ketela T, Colombo I, Mandilaras V, Cabanero M, Bruce JP, Li X, Garg S, Wang L, Chen EX, Gill S, Dhani NC, Zhang W, Pintilie M, Bowering V, Koritzinsky M, Rottapel R, Wouters BG, Oza AM, Joshua AM, Lheureux S (2022).

Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer.

Cancer Research Communications. Article. 2(5):293-306.
[doi:10.1158/2767-9764.CRC-22-0037]
Gil-Ibanez, B, Gil-Moreno, A, Torne, A, Jimenez, AM, Gorostidi, M, Zapardiel, I, Garcia, AT, Diaz-Feijoo, B (2022).

Tumor Size and Oncological Outcomes in Patients with Early Cervical Cancer Treated by Fertility Preservation Surgery: A Multicenter Retrospective Cohort Study

Cancers. Article. 14(9).
[doi:10.3390/cancers14092108]
Gianni, L, Huang, CS, Egle, D, Bermejo, B, Zamagni, C, Thill, M, Anton, A, Zambelli, S, Bianchini, G, Russo, S, Ciruelos, EM, Greil, R, Semiglazov, V, Colleoni, M, Kelly, C, Mariani, G, Del Mastro, L, Maffeis, I, Valagussa, P, Viale, G (2022).

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study*

ANNALS OF ONCOLOGY. Article. 33(5):534-543.
[doi:10.1016/j.annonc.2022.02.004]
Cejalvo JM, Falato C, Villanueva L, Tolosa P, González X, Pascal M, Canes J, Gavilá J, Manso L, Pascual T, Prat A, Salvador F (2022).

Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?

CANCER TREATMENT REVIEWS. Review. 106:102392-102392.
[doi:10.1016/j.ctrv.2022.102392]
Diaz-Anton, B, Madurga, R, Zorita, B, Wasniewski, S, Moreno-Arciniegas, A, Lopez-Melgar, B, Merino, NR, Martin-Asenjo, R, Barrio, P, Escanuela, MGA, Solis, J, Jimenez, FJP, Ciruelos, E, Castellano, JM, Fernandez-Friera, L (2022).

Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters

Esc Heart Failure. Article. 9(2):1127-1137.
[doi:10.1002/ehf2.13782]
Diaz-Feijoo, B, Acosta, U, Torne, A, Gil-Ibanez, B, Hernandez, A, Domingo, S, Bradbury, M, Gil-Moreno, A (2022).

Surgical Outcomes of Laparoscopic Pelvic Lymph Node Debulking during Staging Aortic Lymphadenectomy in Locally Advanced Cervical Cancer: A Multicenter Study

Cancers. Article. 14(8).
[doi:10.3390/cancers14081974]
Glickman, A, Paredes, P, Carreras-Dieguez, N, Ninerola-Baizan, A, Gaba, L, Pahisa, J, Fuste, P, Del Pino, M, Diaz-Feijoo, B, Gonzalez-Bosquet, E, Agusti, N, Sanchez-Izquierdo, N, Fuster, D, Perissinotti, A, Romero, I, Fernandez-Galan, E, Carrasco, JL, Gil-Ibanez, B, Torne, A (2022).

Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [F-18]FDG PET/CT volumetric parameters and tumour markers HE4 and CA125

EUROPEAN RADIOLOGY. Article. 32(4):2200-2208.
[doi:10.1007/s00330-021-08305-x]
Shi Z, Wulfkuhle J, Nowicka M, Gallagher RI, Saura C, Nuciforo PG, Calvo I, Andersen J, Passos-Coelho JL, Gil-Gil MJ, Bermejo B, Pratt DA, Ciruelos EM, Villagrasa P, Wongchenko MJ, Petricoin EF, Oliveira M, Isakoff SJ (2022).

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.

CLINICAL CANCER RESEARCH. Article. 28(5):993-1003.
[doi:10.1158/1078-0432.CCR-21-2498]
Villacampa, G, Tolosa, P, Salvador, F, Villanueva, L, Dienstmann, R, Ciruelos, E, Pascual, T (2022).

Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis

CANCER TREATMENT REVIEWS. Review. 104:102352-102352.
[doi:10.1016/j.ctrv.2022.102352]
Lodewijk I, Bernardini A, Suárez-Cabrera C, Bernal E, Sánchez R, Garcia JL, Rojas K, Morales L, Wang S, Han X, Dueñas M, Paramio JM, Manso L (2022).

Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy.

npj Precision Oncology. Article. 6(1):7-7.
[doi:10.1038/s41698-021-00247-3]
García-García VA, Alameda JP, Page A, Mérida-García A, Navarro M, Tejero A, Paramio JM, García-Fernández RA, Casanova ML (2022).

IKKa Induces Epithelial-Mesenchymal Changes in Mouse Skin Carcinoma Cells That Can Be Partially Reversed by Apigenin.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Article. 23(3).
[doi:10.3390/ijms23031375]
Brasó-Maristany F, Paré L, Chic N, Martínez-Sáez O, Pascual T, Mallafré-Larrosa M, Schettini F, González-Farré B, Sanfeliu E, Martínez D, Galván P, Barnadas E, Salinas B, Tolosa P, Ciruelos E, Carcelero E, Guillén C, Adamo B, Moreno R, Vidal M, Muñoz M, Prat A (2022).

Gene expression profiles of breast cancer metastasis according to organ site.

MOLECULAR ONCOLOGY. Article. 16(1):69-87.
[doi:10.1002/1878-0261.13021]
Díaz-Feijoo B, Acosta Ú, Torné A, Gil-Ibáñez B, Hernández A, Domingo S, Gil-Moreno A (2022).

Laparoscopic debulking of enlarged pelvic nodes during surgical paraaortic staging in locally advanced cervical cancer: a retrospective comparative cohort study.

JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY. Article. 29(1):103-113.
[doi:10.1016/j.jmig.2021.06.027]
De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, Lu J, Ciruelos E, Azim HA, Chatterjee S, Zhou K, Wu J, Menon-Singh L, Zamagni C (2022).

Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.

BREAST CANCER RESEARCH AND TREATMENT. Correction. 191(1):223-224.
[doi:10.1007/s10549-021-06374-6]

2021

Rodríguez M, Alonso-Alonso R, Tomás-Roca L, Rodríguez-Pinilla SM, Manso-Alonso R, Cereceda L, Borregón J, Villaescusa T, Córdoba R, Sánchez-Beato M, Fernández-Miranda I, Betancor I, Bárcena C, García JF, Mollejo M, García-Cosio M, Martin-Acosta P, Climent F, Caballero D, de la Fuente L, Mínguez P, Kessler L, Scholz C, Gualberto A, Mondéjar R, Piris MA (2021).

Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers

Blood Advances. Article. 5(24):5588-5598.
[doi:10.1182/bloodadvances.2021005171]
Santisteban M, Solans BP, Hato L, Urrizola A, Mejías LD, Salgado E, Sánchez-Bayona R, Toledo E, Rodríguez-Spiteri N, Olartecoechea B, Idoate MA, López-Díaz de Cerio A, Inogés S (2021).

Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis.

Therapeutic Advances in Medical Oncology. Article. 13.
[doi:10.1177/17588359211064653]
Alvarez-Mon, MA, Donat-Vargas, C, Santoma-Vilaclara, J, de Anta L, Goena, J, Sanchez-Bayona, R, Mora, F, Ortega, MA, Lahera, G, Rodriguez-Jimenez, R, Quintero, J, alvarez-Mon, M (2021).

Assessment of Antipsychotic Medications on Social Media: Machine Learning Study.

Frontiers in psychiatry. Article. 12:737684-737684.
[doi:10.3389/fpsyt.2021.737684]
Pernas, S, Villagrasa, P, Vivancos, A, Scaltriti, M, Rodon, J, Burgues, O, Nuciforo, P, Canes, J, Pare, L, Dueñas M, Vidal, M, Cejalvo, JM, Perello, A, Llommbard-Cussac, A, Dorca, J, Montaño A, Pascual, T, Oliveira, M, Ribas, G, Rapado, I, Prat, A, Ciruelos, E (2021).

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study.

Frontiers in oncology. Article. 11:744112-744112.
[doi:10.3389/fonc.2021.744112]
Suarez-Cabrera, C, Ojeda-Perez, I, Sanchez-Baltasar, R, Page, A, Bravo, A, Navarro, M, Ramirez, A (2021).

ERAS, a Member of the Ras Superfamily, Acts as an Oncoprotein in the Mammary Gland

Cancers. Article. 13(21).
[doi:10.3390/cancers13215588]
Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Nili Gal-Yam E, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers ED, Curigliano G, Bliss JM, Reis-Filho JS, Colleoni M, Balic M, Cardoso F, Albanell J, Duhem C, Marreaud S, Romagnoli D, Rojas B, Gombos A, Wildiers H, Guerrero-Zotano A, Hall P, Bonetti A, Larsson KF, Degiorgis M, Khodaverdi S, Greil R, Sverrisdóttir Á, Paoli M, Seyll E, Loibl S, Linderholm B, Zoppoli G, Davidson NE, Johannsson OT, Bedard PL, Loi S, Knox S, Cameron DA, Harbeck N, Lasa Montoya M, Brandão M, Vingiani A, Caballero C, Hilbers FS, Yates LR, Benelli M, Venet D, Piccart MJ (2021).

Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative.

CANCER DISCOVERY. Article. 11(11):2796-2811.
[doi:10.1158/2159-8290.CD-20-1647]
Garrigos, L, Saura, C, Martinez-Vila, C, Zambelli, A, Bower, M, Pistilli, B, Lambertini, M, Ottaviani, D, Diamantis, N, Lumsden, A, Pernas, S, Generali, D, Segui, E, Vinas, G, Felip, E, Sanchez, A, Rizzo, G, Santoro, A, Cortellini, A, Perone, Y, Chester, J, Iglesias, M, Betti, M, Vincenzi, B, Libertini, M, Mazzoni, F, Zoratto, F, Berardi, R, Guida, A, Wuerstlein, R, Loizidou, A, Sharkey, R, Company, JA, Matas, M, Saggia, C, Chiudinelli, L, Colomba-Blameble, E, Galazi, M, Mukherjee, U, Van Hemelrijck, M, Marin, M, Strina, C, Prat, A, Pla, H, Ciruelos, EM, Bertuzzi, A, del Mastro, L, Porzio, G, Newsom-Davis, T, Ruiz, I, Delany, MB, Krengli, M, Fotia, V, Viansone, A, Chopra, N, Romeo, M, Salazar, R, Perez, I, d'Avanzo, F, Franchi, M, Milani, M, Pommeret, F, Tucci, M, Pedrazzoli, P, Harbeck, N, Ferrante, D, Pinato, DJ, Gennari, A (2021).

COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

Therapeutic Advances in Medical Oncology. Article. 13.
[doi:10.1177/17588359211053416]
Turner NC, Balmaña J, Poncet C, Goulioti T, Tryfonidis K, Honkoop AH, Zoppoli G, Razis E, Johannsson OT, Colleoni M, Tutt AN, Audeh W, Ignatiadis M, Mailliez A, Trédan O, Musolino A, Vuylsteke P, Juan-Fita MJ, Macpherson IRJ, Kaufman B, Manso L, Goldstein LJ, Ellard SL, Láng I, Jen KY, Adam V, Litière S, Erban J, Cameron DA, BRAVO Steering Committee and the BRAVO investigators (2021).

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.

CLINICAL CANCER RESEARCH. Article. 27(20):5482-5491.
[doi:10.1158/1078-0432.CCR-21-0310]
Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M (2021).

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

ANNALS OF ONCOLOGY. Practice Guideline. 32(10):1216-1235.
[doi:10.1016/j.annonc.2021.06.023]
Fernandez-Lazaro, CI, Romanos-Nanclares, A, Sanchez-Bayona, R, Gea, A, Sayon-Orea, C, Martinez-Gonzalez, MA, Toledo, E (2021).

Dietary calcium, vitamin D, and breast cancer risk in women: findings from the SUN cohort.

EUROPEAN JOURNAL OF NUTRITION. Article. 60(7):3783-3797.
[doi:10.1007/s00394-021-02549-5]
Kahan Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, Ciruelos E, Muñoz M, Bermejo B, Margeli M, Antón A, Casas M, Csöszi T, Murillo L, Morales S, Calvo L, Lang I, Alba E, de la Haba-Rodriguez J, Ramos M, López IÁ, Gal-Yam E, Garcia-Palomo A, Alvarez E, González-Santiago S, Rodríguez CA, Servitja S, Corsaro M, Rodrigálvarez G, Zielinski C, Martín M (2021).

Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.

EUROPEAN JOURNAL OF CANCER. Article. 156:70-82.
[doi:10.1016/j.ejca.2021.07.004]
De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, Lu J, Ciruelos E, Azim HA, Chatterjee S, Zhou K, Wu J, Menon-Singh L, Zamagni C (2021).

Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.

BREAST CANCER RESEARCH AND TREATMENT. Article. 189(3):689-699.
[doi:10.1007/s10549-021-06334-0]
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T, PERUSE investigators (2021).

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.

ANNALS OF ONCOLOGY. Article. 32(10):1245-1255.
[doi:10.1016/j.annonc.2021.06.024]
Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA (2021).

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

ANNALS OF ONCOLOGY. Article. 32(9):1148-1156.
[doi:10.1016/j.annonc.2021.06.002]
Benito V, Lubrano A, Pérez-Regadera JF, Torné A, Gil-Moreno A, Tejerizo-Garcia Á, Vergés R, Díaz-Feijoo B, SEGO Spain-GOG Group (2021).

Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group.

GYNECOLOGIC ONCOLOGY. Article. 162(2):407-412.
[doi:10.1016/j.ygyno.2021.06.005]
Garcia-Garcia, VA, Alameda, JP, Page, A, Casanova, ML (2021).

Role of NF-kappa B in Ageing and Age-Related Diseases: Lessons from Genetically Modified Mouse Models

Cells. Review. 10(8).
[doi:10.3390/cells10081906]
Gil-Gil M, Alba E, Gavilá J, de la Haba-Rodríguez J, Ciruelos E, Tolosa P, Candini D, Llombart-Cussac A (2021).

The role of CDK4/6 inhibitors in early breast cancer.

Breast. Article. 58:160-169.
[doi:10.1016/j.breast.2021.05.008]
Perez-Fidalgo JA, Cortés A, Guerra E, García Y, Iglesias M, Bohn Sarmiento U, Calvo García E, Manso Sánchez L, Santaballa A, Oaknin A, Redondo A, Rubio MJ, González-Martín A (2021).

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).

Esmo Open. Article. 6(4):100212-100212.
[doi:10.1016/j.esmoop.2021.100212]
Gil-Gil, MJ, Bellet, M, Bergamino, M, Morales, S, Barnadas, A, Manso, L, Saura, C, Fernandez-Ortega, A, Garcia-Martinez, E, Martinez-Janez, N, Mele, M, Villagrasa, P, Celiz, P, Martin, XP, Ciruelos, E, Pernas, S (2021).

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study

Frontiers in oncology. Article. 11.
[doi:10.3389/fonc.2021.645026]
Sanchez-Bayona R, Gardeazabal I, Romanos-Nanclares A, Fernandez-Lazaro CI, Alvarez-Alvarez I, Ruiz-Canela M, Gea A, Martinez-Gonzalez MA, Santisteban M, Toledo E (2021).

Leisure-time physical activity, sedentary behavior, and risk of breast cancer: Results from the SUN ('Seguimiento Universidad De Navarra') project.

PREVENTIVE MEDICINE. Article. 148:106535-106535.
[doi:10.1016/j.ypmed.2021.106535]
Cabrera S, Barahona-Orpinell M, Almansa-González C, Padilla-Iserte P, Bebia V, Martí L, Tejerizo-García Á, Domingo S, Gil-Moreno A (2021).

Combined use of ICG and technetium does not improve sentinel lymph node detection in endometrial cancer: Results of the COMBITEC study.

GYNECOLOGIC ONCOLOGY. Article. 162(1):32-37.
[doi:10.1016/j.ygyno.2021.05.002]
Chic N, Schettini F, Brasó-Maristany F, Sanfeliu E, Adamo B, Vidal M, Martínez D, Galván P, González-Farré B, Cortés J, Gavilá J, Saura C, Oliveira M, Pernas S, Martínez-Sáez O, Soberino J, Ciruelos E, Carey LA, Muñoz M, Perou CM, Pascual T, Bellet M, Prat A (2021).

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy.

EBioMedicine. Article. 69:103451-103451.
[doi:10.1016/j.ebiom.2021.103451]
Alameda, JP, Garcia-Garcia, VA, Lopez, S, Hernando, A, Page, A, Navarro, M, Moreno-Maldonado, R, Paramio, JM, Ramirez, A, Garcia-Fernandez, RA, Casanova, ML (2021).

CYLD Inhibits the Development of Skin Squamous Cell Tumors in Immunocompetent Mice

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Article. 22(13).
[doi:10.3390/ijms22136736]
Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, André F (2021).

Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.

JOURNAL OF CLINICAL ONCOLOGY. Article. 39(18):2005-2015.
[doi:10.1200/JCO.20.01139]
Zapardiel, I, Alvarez, J, Barahona, M, Barri, P, Boldo, A, Bresco, P, Gasca, I, Jaunarena, I, Kucukmetin, A, Mancebo, G, Otero, B, Roldan, F, Rovira, R, Suarez, E, Tejerizo, A, Torrent, A, Gorostidi, M (2021).

Utility of Intraoperative Fluorescence Imaging in Gynecologic Surgery: Systematic Review and Consensus Statement

ANNALS OF SURGICAL ONCOLOGY. Review. 28(6):3266-3278.
[doi:10.1245/s10434-020-09222-x]
Oliver-Perez MR, Magriña J, Villalain-Gonzalez C, Jimenez-Lopez JS, Lopez-Gonzalez G, Barcena C, Martinez-Biosques C, Gil-Ibañez B, Tejerizo-Garcia A (2021).

Lymphovascular space invasion in endometrial carcinoma: Tumor size and location matter.

SURGICAL ONCOLOGY-OXFORD. Article. 37:101541-101541.
[doi:10.1016/j.suronc.2021.101541]
Redondo A, Oaknin A, Rubio MJ, Barretina-Ginesta MP, de Juan A, Manso L, Romero I, Martin-Lorente C, Poveda A, Gonzalez-Martin A (2021).

Management of advanced ovarian cancer in Spain: an expert Delphi consensus.

J OVARIAN RES. Article. 14(1):72-72.
[doi:10.1186/s13048-021-00816-x]
Redondo, A, Guerra, E, Manso, L, Martin-Lorente, C, Martinez-Garcia, J, Perez-Fidalgo, JA, Varela, MQ, Rubio, MJ, Barretina-Ginesta, MP, Gonzalez-Martin, A (2021).

SEOM clinical guideline in ovarian cancer (2020)

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 23(5):961-968.
[doi:10.1007/s12094-020-02545-x]
Macías M, García-Cortés Á, Torres M, Ancizu-Marckert J, Ignacio Pascual J, Díez-Caballero F, Enrique Robles J, Rosell D, Miñana B, Mateos B, Ajona D, Sánchez-Bayona R, Bedialauneta O, Chocarro S, Navarro A, Andueza MP, Gúrpide A, Luis Perez-Gracia J, Alegre E, González Á (2021).

Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients.

CYTOKINE. Article. 141:155471-155471.
[doi:10.1016/j.cyto.2021.155471]
Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A, Vindeløv SD, Chen M, Harris JR, Smith M, Nicacio LV, Teng MSL, Laenen A, Rangwala R, Manso L, Mirza M, Monk BJ, Vergote I, innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators (2021).

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.

LANCET ONCOLOGY. Article. 22(5):609-619.
[doi:10.1016/S1470-2045(21)00056-5]
Pascual T, Oliveira M, Ciruelos E, Bellet Ezquerra M, Saura C, Gavilá J, Pernas S, Muñoz M, Vidal MJ, Margelí Vila M, Cejalvo JM, González-Farré B, Espinosa-Bravo M, Cruz J, Salvador-Bofill FJ, Guerra JA, Luna Barrera AM, Arumi de Dios M, Esker S, Fan PD, Martínez-Sáez O, Villacampa G, Paré L, Ferrero-Cafiero JM, Villagrasa P, Prat A (2021).

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer.

Frontiers in oncology. Article. 11:638482-638482.
[doi:10.3389/fonc.2021.638482]
Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso L, Zamarchi R, Antelo ML, De Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein HJ, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HS (2021).

Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. Article. 113(4):443-452.
[doi:10.1093/jnci/djaa113]
Goetz, MP, Okera, M, Wildiers, H, Campone, M, Grischke, EM, Manso, L, Andre, VAM, Chouaki, N, San Antonio, B, Toi, M, Sledge, GW (2021).

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials

BREAST CANCER RESEARCH AND TREATMENT. Article. 186(2):417-428.
[doi:10.1007/s10549-020-06029-y]
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S (2021).

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.

LANCET ONCOLOGY. Article. 22(4):489-498.
[doi:10.1016/S1470-2045(21)00034-6]
Ortiz-Ruiz A, Ruiz-Heredia Y, Morales ML, Aguilar-Garrido P, García-Ortiz A, Valeri A, Bárcena C, García-Martin RM, Garrido V, Moreno L, Gimenez A, Navarro-Aguadero MÁ, Velasco-Estevez M, Lospitao E, Cedena MT, Barrio S, Martínez-López J, Linares M, Gallardo M (2021).

Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma.

Cancers. Article. 13(7).
[doi:10.3390/cancers13071662]
Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, Munoz, M, Bermejo B, Margeli M, Anton A, Kahan Z, Csoszi, T, Casas MI, Murillo L, Morales S, Alba E, Gal-Yam E, Guerrero-Zotano A, Calvo L, de la Haba-Rodriguez J, Ramos M, Alvarez I, Garcia-Palomo A, Bartlett, CH, Koehler M, Caballero R, Corsaro M, Huang X, Garcia-Sáenz JA, Chacón JI, Swift C, Thallinger C, Gil-Gil M (2021).

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL

ANNALS OF ONCOLOGY. Article. 32(4):488-499.
[doi:10.1016/j.annonc.2020.12.013]
Muñoz-Hernández P, Serrano-Pardo R, Bárcena C, Jiménez-Heffernan JA (2021).

Cytoplasmic vacuolization in breast implant-associated anaplastic large-cell lymphoma.

DIAGNOSTIC CYTOPATHOLOGY. Editorial Material. 49(4):549-551.
[doi:10.1002/dc.24712]
Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, Paré L, Pernas S, Muñoz M, Oliveira M, Vidal M, Llombart-Cussac A, Cortés J, Galván P, Bermejo B, Martínez N, López R, Morales S, Garau I, Manso L, Alarcón J, Martínez E, Villagrasa P, Prat A, Nuciforo P (2021).

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer.

npj Precision Oncology. Article. 5(1):23-23.
[doi:10.1038/s41698-021-00163-6]
Valdivia-Mazeyra MF, Salas C, Nieves-Alonso JM, Martín-Fragueiro L, Bárcena C, Muñoz-Hernández P, Villar-Zarra K, Martín-López J, Ramasco-Rueda F, Fraga J, Jiménez-Heffernan JA (2021).

Increased number of pulmonary megakaryocytes in COVID-19 patients with diffuse alveolar damage: an autopsy study with clinical correlation and review of the literature.

VIRCHOWS ARCHIV. Review. 478(3):1-10.
[doi:10.1007/s00428-020-02926-1]
Patiño-García A, Guruceaga E, Segura V, Sánchez Bayona R, Andueza MP, Tamayo Uria I, Serrano G, Fusco JP, Pajares MJ, Gurpide A, Ocón M, Sanmamed MF, Rodriguez Ruiz M, Melero I, Lozano MD, de Andrea C, Pita G, Gonzalez-Neira A, Gonzalez A, Zulueta JJ, Montuenga LM, Pio R, Perez-Gracia JL (2021).

Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma.

Translational lung cancer research. Article. 10(3):1327-1337.
[doi:10.21037/tlcr-20-1197]
Mouron, S, Manso, L, Caleiras, E, Rodriguez-Peralto, JL, Rueda, OM, Caldas, C, Colomer, R, Quintela-Fandino, M, Bueno, MJ (2021).

FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1

BREAST CANCER RESEARCH. Article. 23(1):21-21.
[doi:10.1186/s13058-021-01398-8]
Martinez-Saez, O, Pascual, T, Braso-Maristany, F, Chic, N, Gonzalez-Farre, B, Sanfeliu, E, Rodriguez, A, Martinez, D, Galvan, P, Rodriguez, AB, Schettini, F, Conte, B, Vidal, M, Adamo, B, Martinez, A, Muñoz M, Moreno, R, Villagrasa, P, Salvador, F, Ciruelos, EM, Faull, I, Odegaard, JI, Prat, A (2021).

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

npj Breast Cancer. Article. 7(1):8-8.
[doi:10.1038/s41523-021-00218-8]
Torne, A, Pahisa, J, Ordi, J, Fuste, P, Diaz-Feijoo, B, Glickman, A, Paredes, P, Rovirosa, A, Gaba, L, Saco, A, Nicolau, C, Carreras, N, Agusti, N, Vidal-Sicart, S, Gil-Ibanez, B, del Pino, M (2021).

Oncological Results of Laparoscopically Assisted Radical Vaginal Hysterectomy in Early-Stage Cervical Cancer: Should We Really Abandon Minimally Invasive Surgery?

Cancers. Article. 13(4).
[doi:10.3390/cancers13040846]
Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, Tjan-Heijnen V, Martin M, Rottey S, Generali D, Campone M, Cristofanilli M, Pusztai L, Peeters M, Berchem G, Cortes J, Ruhstaller T, Ciruelos E, Rugo HS, Jerusalem G (2021).

Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology.

Jco Global Oncology. Article. 7:162-172.
[doi:10.1200/GO.20.00589]
Andre, F, Ciruelos, EM, Juric, D, Loibl, S, Campone, M, Mayer, IA, Rubovszky, G, Yamashita, T, Kaufman, B, Lu, YS, Inoue, K, Papai, Z, Takahashi, M, Ghaznawi, F, Mills, D, Kaper, M, Miller, M, Conte, PF, Iwata, H, Rugo, HS (2021).

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1

ANNALS OF ONCOLOGY. Article. 32(2):208-217.
[doi:10.1016/j.annonc.2020.11.011]
Aguilera-Buenosvinos, I, Fernandez-Lazaro, CI, Romanos-Nanclares, A, Gea, A, Sanchez-Bayona, R, Martin-Moreno, JM, Martinez-Gonzalez, MA, Toledo, E (2021).

Dairy Consumption and Incidence of Breast Cancer in the 'Seguimiento Universidad de Navarra' (SUN) Project

Nutrients. Article. 13(2).
[doi:10.3390/nu13020687]
Sanchez-Bayona, R, Sayon-Orea, C, Gardeazabal, I, Llorca, J, Gea, A, Santisteban, M, Martin-Moreno, JM, Toledo, E (2021).

Body shape trajectories and risk of breast cancer: results from the SUN ('Seguimiento Universidad De Navarra') Project

PUBLIC HEALTH NUTRITION. Article. 24(3):467-475.
[doi:10.1017/S1368980020004322]
Jimenez-Heffernan JA, Alvarez F, Muñoz-Hernández P, Bárcena C, Azorin D, Bernal I, PEREZ CAMPOS, ANA ISABEL (2021).

Cytologic Features of Ventricular Tumors of the Central Nervous System: A Review with Emphasis on Diff-Quik Stained Smears.

ACTA CYTOLOGICA. Review. 65(2):1-12.
[doi:10.1159/000512723]

2020

Manso, L, Hernando, C, Galan, M, Oliveira, M, Cabrera, MA, Bratos, R, Rodriguez, CA, Ruiz-Borrego, M, Blanch, S, Llombart-Cussac, A, Delgado-Mingorance, JI, Alvarez-Busto, I, Gallegos, I, Gonzalez-Cortijo, L, Morales, S, Aguirre, E, Hernando, BA, Ballesteros, A, Ales-Martinez, JE, Reboredo, C, Oltra, A, Gonzalez-Cao, M, Santisteban, M, Malon, D, Echeverria, I, Garcia-Garre, E, Vega, E, Servitja, S, Andres, R, Robles, CE, Lopez, R, Galve, E, Echarri, MJ, Legeren, M, Moreno, F (2020).

Palbociclib combined with endocrine therapy in heavily pretreated HR(+)/HER2(-) advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).

Breast. Article. 54:286-292.
[doi:10.1016/j.breast.2020.11.005]
Prat, A, Tsai, YH, Pascual, T, Pare, L, Adamo, B, Vidal, M, Braso-Maristany, F, Galvan, P, Brase, JC, Rodrik-Outmezguine, V, Johnston, S, Ciruelos, E, Parker, JS (2020).

A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.

CLINICAL CANCER RESEARCH. Article. 26(23):6141-6148.
[doi:10.1158/1078-0432.CCR-20-2793]
Ciruelos, E, Villagrasa, P, Pascual, T, Oliveira, M, Pernas, S, Pare, L, Escriva-de-Romani, S, Manso, L, Adamo, B, Martinez, E, Cortes, J, Vazquez, S, Perello, A, Garau, I, Mele, M, Martinez, N, Montano, A, Bermejo, B, Morales, S, Echarri, MJ, Vega, E, Gonzalez-Farre, B, Martinez, D, Galvan, P, Canes, J, Nuciforo, P, Gonzalez, X, Prat, A (2020).

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

CLINICAL CANCER RESEARCH. Article. 26(22):5820-5829.
[doi:10.1158/1078-0432.CCR-20-0844]
Quintela-Fandino, M, Holgado, E, Manso, L, Morales, S, Bermejo, B, Colomer, R, Apala, JV, Blanco, R, Muñoz M, Caleiras, E, Iranzo, V, Martinez, M, Dominguez, O, Hornedo, J, Gonzalez-Cortijo, L, Cortes, J, Gasol Cudos A, Malon, D, Lopez-Alonso, A, Moreno-Ortiz, MC, Mouron, S, Mañes S (2020).

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.

BREAST CANCER RESEARCH. Article. 22(1):124-124.
[doi:10.1186/s13058-020-01362-y]
Garrido-Castro, AC, Saura, C, Barroso-Sousa, R, Guo, H, Ciruelos, E, Bermejo, B, Gavila, J, Serra, V, Prat, A, Pare, L, Celiz, P, Villagrasa, P, Li, YS, Savoie, J, Xu, Z, Arteaga, CL, Krop, IE, Solit, DB, Mills, GB, Cantley, LC, Winer, EP, Lin, NU, Rodon, J (2020).

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.

BREAST CANCER RESEARCH. Article. 22(1):120-120.
[doi:10.1186/s13058-020-01354-y]
Gonzalez-Santiago, S, Saura, C, Ciruelos, E, Alonso, JL, de la Morena, P, Santisteban Eslava M, Gallegos Sancho MI, de Luna, A, Dalmau, E, Servitja, S, Ruiz Borrego M, Chacon, JI (2020).

Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).

BREAST CANCER RESEARCH AND TREATMENT. Article. 184(2):469-479.
[doi:10.1007/s10549-020-05866-1]
Tjokrowidjaja, A, Lee, CK, Friedlander, M, Gebski, V, Gladieff, L, Ledermann, J, Penson, R, Oza, A, Korach, J, Huzarski, T, Manso, L, Pisano, C, Asher, R, Lord, SJ, Kim, SI, Lee, JY, Colombo, N, Park-Simon, TW, Fujiwara, K, Sonke, G, Vergote, I, Kim, JW, Pujade-Lauraine, E (2020).

Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.

EUROPEAN JOURNAL OF CANCER. Article. 139:59-67.
[doi:10.1016/j.ejca.2020.08.021]
Martin, M, Garcia-Saenz, JA, Manso, L, Llombart, A, Cassinello, A, Atienza, M, Ringeisen, F, Ciruelos, E (2020).

Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer

FUTURE ONCOLOGY. Review. 16(33):2763-2778.
[doi:10.2217/fon-2020-0604]
Prat, A, Guarneri, V, Pare, L, Griguolo, G, Pascual, T, Dieci, MV, Chic, N, Gonzalez-Farre, B, Frassoldati, A, Sanfeliu, E, Cejalvo, JM, Munoz, M, Bisagni, G, Braso-Maristany, F, Urso, L, Vidal, M, Brandes, AA, Adamo, B, Musolino, A, Miglietta, F, Conte, B, Oliveira, M, Saura, C, Pernas, S, Alarcon, J, Llombart-Cussac, A, Cortes, J, Manso, L, Lopez, R, Ciruelos, E, Schettini, F, Villagrasa, P, Carey, LA, Perou, CM, Piacentini, F, D'Amico, R, Tagtiapco, E, Parker, JS, Conte, P (2020).

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

LANCET ONCOLOGY. Article. 21(11):1455-1464.
Schettini, F, Sobhani, N, Ianza, A, Triulzi, T, Molteni, A, Lazzari, MC, Strina, C, Milani, M, Corona, SP, Sirico, M, Bernocchi, O, Giudici, F, Cappelletti, MR, Ciruelos, E, Jerusalem, G, Loi, S, Fox, SB, Generali, D (2020).

Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study

BREAST CANCER RESEARCH AND TREATMENT. Article. 184(2):421-431.
[doi:10.1007/s10549-020-05856-3]
Yamada, A, Kawasaki, M, Miake, Y, Yamada, Y, Blackburn, J, Kawasaki, K, Trakanant, S, Nagai, T, Nihara, J, Kudo, T, Meguro, F, Schmidt-Ullrich, R, Liu, BG, Hu, YL, Page, A, Ramirez, A, Sharpe, PT, Maeda, T, Takagi, R, Ohazama, A (2020).

Overactivation of the NF-kappaB pathway impairs molar enamel formation.

ORAL DISEASES. Article. 26(7):1513-1522.
[doi:10.1111/odi.13384]
Ciruelos, E, Jerusalem, G, Martin, M, Tjan-Heijnen VCG, Neven, P, Gavila, J, Montemurro, F, Generali, D, Lang, I, Martinez-Serrano, MJ, Perello, MF, Conte, P (2020).

Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 22(10):1857-1866.
[doi:10.1007/s12094-020-02327-5]
Tratwal, J, Bekri, D, Boussema, C, Sarkis, R, Kunz, N, Koliqi, T, Rojas-Sutterlin, S, Schyrr, F, Tavakol, DN, Campos, V, Scheller, EL, Sarro, R, Barcena, C, Bisig, B, Nardi, V, de Leval, L, Burri, O, Naveiras, O (2020).

MarrowQuant Across Aging and Aplasia: A Digital Pathology Workflow for Quantification of Bone Marrow Compartments in Histological Sections.

Frontiers in Endocrinology. Article. 11:480-480.
[doi:10.3389/fendo.2020.00480]
Tolosa, P, Sanchez-Torre, A, de Cabo, HB, Sanchez-Bayona, R, Herrera, M, Yarza, R, Lema, L, Manso, L, Ciruelos, E (2020).

Impact of CDK 4/6i withdrawal or dose adjustment on COVID-19 incidence in HR+/HER2-mBC patients during the pandemic.

CLINICAL CANCER RESEARCH. Meeting Abstract. 26(18).
Lago, V, Fotopoulou, C, Chiantera, V, Minig, L, Gil-Moreno, A, Cascales-Campos, PA, Jurado, M, Tejerizo, A, Padilla-Iserte, P, Malune, ME, Di Donna, MC, Marina, T, Sanchez-Iglesias, JL, Chiva, L, Olloqui, A, Matute, L, Garcia-Granero, A, Cardenas-Rebollo, JM, Domingo, S (2020).

Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction.

GYNECOLOGIC ONCOLOGY. Article. 158(3):603-607.
[doi:10.1016/j.ygyno.2020.05.047]
Jerusalem, G, Onesti, CE, Generali, DG, Harbeck, N, Wildiers, H, Curigliano, G, Campone, M, Tjan-Heijnen, V, Martin, M, Cristofanilli, M, Pusztai, L, Bartsch, R, Peeters, M, Berchem, G, Tagliamento, M, Cortes, J, Ruhstaller, T, Ciruelos, EM, Rottey, S, Rugo, HS (2020).

Expected medium and long term impact of the COVID-19 outbreak in oncology

ANNALS OF ONCOLOGY. Meeting Abstract. 31:1205-1206.
[doi:10.1016/j.annonc.2020.08.2317]
Diaz-Feijoo, B, Franco, S, Torne, A, Benito, V, Hernandez, A, Lago, V, Rovira, R, Acosta, U, Agusti, N, Gil-Moreno, A, Gil-Ibanez, B, Bebia, V, Tejerizo, A, Perez-Regadera, JF, Lubrano, A, Gonzalez, C, Domingo, S, Ruiz, R, Cobos, P, Luna-Guibourg, R, Gilabert-Estelles, J, Chipiriliu, D, Llueca, A, Piquer, L, Coronado, P, Gracia, M, SEGO Spain-GOG Grp (2020).

Implications of extraperitoneal paraaortic lymphadenectomy to the left renal vein in locally advanced cervical cancer. A Spanish multicenter study

GYNECOLOGIC ONCOLOGY. Article. 158(2):287-293.
[doi:10.1016/j.ygyno.2020.05.004]
Rugo, HS, Andre, F, Yamashita, T, Cerda, H, Toledano, I, Stemmer, SM, Jurado, JC, Juric, D, Mayer, I, Ciruelos, EM, Iwata, H, Conte, P, Campone, M, Wilke, C, Mills, D, Lteif, A, Miller, M, Gaudenzi, F, Loibl, S (2020).

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.

ANNALS OF ONCOLOGY. Article. 31(8):1001-1010.
[doi:10.1016/j.annonc.2020.05.001]
Smyth, LM, Tamura, K, Oliveira, M, Ciruelos, EM, Mayer, IA, Sablin, MP, Biganzoli, L, Ambrose, HJ, Ashton, J, Barnicle, A, Cashell, D, Corcoran, C, de Bruin, EC, Foxley, A, Hauser, J, Lindemann JPO, Maudsley, R, McEwen, R, Moschetta, M, Pass, M, Rowlands, V, Schiavon, G, Banerji, U, Scaltriti, M, Taylor, BS, Chandarlapaty, S, Baselga, J, Hyman, DM (2020).

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 (E17K)-Mutant, ER-Positive Metastatic Breast Cancer.

CLINICAL CANCER RESEARCH. Article. 26(15):3947-3957.
[doi:10.1158/1078-0432.CCR-19-3953]
Ciruelos, EM, Montaño A, Rodriguez, CA, Gonzalez-Flores, E, Lluch, A, Garrigos, L, Quiroga, V, Anton, A, Malon, D, Chacon, JI, Velasco, M, Gonzalez-Cortijo, L, Jolis, L, Echarri, MJ, Muñoz M, Pascual, T, Amigo, Y, Casas, M, Carrasco, E, Casas, A (2020).

Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).

EUROPEAN JOURNAL OF CANCER CARE. Article. 29(4).
[doi:10.1111/ecc.13253]
Corona SP, Giudici F, Jerusalem G, Ciruelos E, Strina C, Sirico M, Bernocchi O, Milani M, Dester M, Ziglioli N, Barbieri G, Cervoni V, Montemurro F, Generali D (2020).

Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.

Oncotarget. Article. 11(23):2172-2181.
[doi:10.18632/oncotarget.27612]
Herrera Juarez M, Tolosa Ortega P, Sanchez de Torre A, Ciruelos Gil E (2020).

Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features.

Breast Care. Review. 15(3):208-216.
[doi:10.1159/000508758]
Manso, L, De Velasco, G, Paz-Ares, L (2020).

Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain.

Esmo Open. Letter. 4(Suppl 2).
[doi:10.1136/esmoopen-2020-000828]
Pérez Ramírez S, del Monte-Millan, M, Lopez-Tarruella, S, Martínez Jáñez N, Marquez-Rodas, I, Lobo Samper F, Izarzugaza Perón Y, Rubio Terres C, Rubio Rodríguez D, Garcia-Saenz, JA, Moreno Antón F, Zamora Auñón P, Arroyo Yustos M, Lara Álvarez MÁ, Ciruelos Gil EM, Manso Sánchez L, Echarri González MJ, Guerra Martínez JA, Jara Sánchez C, Bueno Muiño C, García Adrián S, Carrión Galindo JR, Valentín Maganto V, Martin, M (2020).

Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience.

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 22(5):717-724.
[doi:10.1007/s12094-019-02176-x]
Tejerizo-Garcia, A, Olloqui, A, Lopez, G, Alvarez-Conejo, C, Caso-Maestro, O, Diez, A (2020).

Step-by-step total pelviperitonectomy with modified posterior pelvic exenteration.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Editorial Material. 30(4):558-558.
[doi:10.1136/ijgc-2019-000984]
Swain, SM, Miles, D, Kim, SB, Im, YH, Im, SA, Semiglazov, V, Ciruelos, E, Schneeweiss, A, Loi, S, Monturus, E, Clark, E, Knott, A, Restuccia, E, Benyunes, MC, Cortes, J, CLEOPATRA Study Grp (2020).

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

LANCET ONCOLOGY. Article. 21(4):519-530.
[doi:10.1016/S1470-2045(19)30863-0]
Gavilá J, De La Haba J, Bermejo B, Rodríguez-Lescure Á, Antón A, Ciruelos E, Brunet J, Muñoz-Couselo E, Santisteban M, Rodríguez Sánchez CA, Santaballa A, Sánchez Rovira P, García Sáenz JÁ, Ruiz-Borrego M, Guerrero-Zotano AL, Huerta M, Cotes-Sanchís A, Lao Romera J, Aguirre E, Cortés J, Llombart-Cussac A (2020).

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 22(3):420-428.
[doi:10.1007/s12094-019-02145-4]
Cortes, J, Ciruelos, E, Perez-Garcia, J, Albanell, J, Garcia-Estevez, L, Ruiz-Borrego, M, Espinosa, R, Gallegos, I, Gonzalez, S, Alvarez, I, Llombart, A (2020).

Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients.

CANCER TREATMENT REVIEWS. Review. 83:101944-101944.
[doi:10.1016/j.ctrv.2019.101944]
Ramis-Zaldivar, JE, Gonzalez-Farre, B, Balague, O, Celis, V, Nadeu, F, Salmeron-Villalobos, J, Andres, M, Martin-Guerrero, I, Garrido-Pontnou, M, Gaafar, A, Suñol M, Barcena, C, Garcia-Bragado, F, Andion, M, Azorin, D, Astigarraga, I, Sagaseta de Ilurdoz M, Sabado, C, Gallego, S, Verdu-Amoros, J, Fernandez-Delgado, R, Perez, V, Tapia, G, Mozos, A, Torrent, M, Solano-Paez, P, Rivas-Delgado, A, Dlouhy, I, Clot, G, Enjuanes, A, Lopez-Guillermo, A, Galera, P, Oberley, MJ, Maguire, A, Ramsower, C, Rimsza, LM, Quintanilla-Martinez, L, Jaffe, ES, Campo, E, Salaverria, I (2020).

IRF4-rearranged Large B-cell lymphoma (LBCL) has a genomic profile distinct to other LBCL in children and young adults.

BLOOD. Article. 135(4):274-286.
[doi:10.1182/blood.2019002699]
Braso-Maristany, F, Griguolo, G, Pascual, T, Pare, L, Nuciforo, P, Llombart-Cussac, A, Bermejo, B, Oliveira, M, Morales, S, Martinez, N, Vidal, M, Adamo, B, Martinez, O, Pernas, S, Lopez, R, Munoz, M, Chic, N, Galvan, P, Garau, I, Manso, L, Alarcon, J, Martinez, E, Gregorio, S, Gomis, RR, Villagrasa, P, Cortes, J, Ciruelos, E, Prat, A (2020).

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

NATURE COMMUNICATIONS. Article. 11(1):385-385.
[doi:10.1038/s41467-019-14111-3]
Page, A, Bravo, A, Suarez-Cabrera, C, Sanchez-Baltasar, R, Oteo, M, Morcillo, MA, Casanova, ML, Segovia, JC, Navarro, M, Ramirez, A (2020).

IKKß overexpression together with a lack of tumour suppressor genes causes ameloblastic odontomas in mice.

INTERNATIONAL JOURNAL OF ORAL SCIENCE. Article. 12(1):1-1.
[doi:10.1038/s41368-019-0067-9]
Cedena, MT, Martin-Clavero, E, Wong, S, Shah, N, Bahri, N, Alonso, R, Barcenas, C, Valeri, A, Salazar Tabares J, Sanchez-Pina, J, Cuellar, C, Martin, T, Wolf, J, Lahuerta, JJ, Martinez-Lopez, J (2020).

The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.

PLOS ONE. Article. 15(8).
[doi:10.1371/journal.pone.0237155]
Oliver, R, Betoret, RM (2020).

Treatment of primary and recurrent vaginal/vulva cancer

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Editorial Material. 30:18-18.
Prat, A, Saura, C, Pascual, T, Hernando, C, Muñoz M, Pare, L, González Farré B, Fernandez, PL, Galvan, P, Chic, N, González Farré X, Oliveira, M, Gil-Gil, M, Arumi, M, Ferrer, N, Montaño A, Izarzugaza, Y, Llombart-Cussac, A, Bratos, R, González Santiago S, Martinez, E, Hoyos, S, Rojas, B, Virizuela, JA, Ortega, V, Lopez, R, Celiz, P, Ciruelos, E, Villagrasa, P, Gavila, J (2020).

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.

LANCET ONCOLOGY. Article. 21(1):33-43.
[doi:10.1016/S1470-2045(19)30786-7]
Jimenez-Heffernan, JA, Munoz-Hernandez, P, Barcena, C (2020).

Kikuchi-Fujimoto Disease-Like Inflammatory Reaction in a Silicone Breast Implant Seroma.

ACTA CYTOLOGICA. Article. 64(4):1-4.
[doi:10.1159/000505253]
Quintela-Fandino, M, Morales, S, Cortes-Salgado, A, Manso, L, Apala, JV, Muñoz M, Gasol Cudos A, Salla Fortuny J, Gion, M, Lopez-Alonso, A, Cortes, J, Guerra, J, Malon, D, Caleiras, E, Mulero, F, Mouron, S (2020).

Randomized phase 0/I trial of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early HER2-negative breast cancer.

CLINICAL CANCER RESEARCH. Article. 26(1):35-45.
[doi:10.1158/1078-0432.CCR-19-2023]

2019

Lopez-Gomez, V, Yarza, R, Munoz-Gonzalez, H, Revilta, E, Enrech, S, Gonzalez-Valle, O, Tolosa, P, Ciruelos, E (2019).

Ribociclib-Related Stevens-Johnson Syndrome: Oncologic Awareness, Case Report, and Literature Review

JOURNAL OF BREAST CANCER. Review. 22(4):661-666.
[doi:10.4048/jbc.2019.22.e44]
Aubel, D, Loibl, S, Kaufman, B, Lu, YS, Juric, D, Mayer, I, Ciruelos, E, Campone, M, Conte, P, Iwata, H, Rugo, H, Ghaznawi, F, Gillis, K, Mills, D, Andre, F (2019).

A PLAIN-LANGUAGE SUMMARY OF THE SOLAR-1 TRIAL: STUDYING ALPELISIB WITH FULVESTRANT IN PATIENTS WITH HR+, HER2-ADVANCED BREAST CANCER WHO HAD PREVIOUSLY RECEIVED AN AROMATASE INHIBITOR

Breast. Meeting Abstract. 48:48-48.
[doi:10.1016/S0960-9776(19)30680-0]
Ciruelos, E, Apellániz-Ruiz M, Cantos, B, Martinez-J??ez, N, Bueno-Mui?o, C, Echarri, MJ, Enrech, S, Guerra, JA, Manso, L, Pascual, T, Dominguez, C, Gonzalo, JF, Sanz, JL, Rodriguez-Antona, C, Sepúlveda JM (2019).

A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.

ONCOLOGIST. Article. 24(11):1024-1033.
[doi:10.1634/theoncologist.2017-0664]
Ciruelos, EM, Diaz, MN, Isla, MD, Lopez, R, Bernabe, R, Gonzalez, E, Cirauqui, B, Coves, J, Morales, S, Arcediano, A, Barneto, I, Cerezuela, P, Illarramendi, JJ, Morales, C, Ponce, S (2019).

Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer.

EUROPEAN JOURNAL OF CANCER CARE. Article. 28(6).
[doi:10.1111/ecc.13164]
García Rojo E, González Padilla DA, Castelo Loureiro A, Parrilla Rubio L, Tejido Sánchez Á, Guerrero Ramos F (2019).

New case of secondary bladder amyloidosis with massive hematuria-role of intravesical instillations with dimethyl sulfoxide.

Translational Andrology and Urology. Article. 8(5):548-555.
[doi:10.21037/tau.2019.09.22]
Jimenez-Heffernan, JA, Romero, J, Barcena, C, Cañizal JM (2019).

Cytological features of rosette-forming glioneuronal tumor of the fourth ventricle.

DIAGNOSTIC CYTOPATHOLOGY. Article. 47(10):1082-1085.
[doi:10.1002/dc.24273]
Marin-Rubio, JL, Perez-Gomez, E, Fernandez-Piqueras, J, Villa-Morales, M (2019).

S194-P-FADD as a marker of aggressiveness and poor prognosis in human T-cell lymphoblastic lymphoma.

CARCINOGENESIS. Article. 40(10):1260-1268.
[doi:10.1093/carcin/bgz041]
Galiana, A, Tabuenca, M, Marin, M, Aragon, S, Ciruelos, E, Torrens, J, Ruiz, S, Martinez, E, Godigna, V, Vega, D, Estenoz, J (2019).

Axillary Node Staging After Neoadjuvant Systemic Therapy Using Sentinel Node Biopsy and Radioiodine Seed Localization in Breast Cancer Patients. First Experiences in our Center

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. Meeting Abstract. 46(SUPPL 1):521-521.
Adamo, B, Bellet, M, Pare, L, Pascual, T, Vidal, M, Pérez Fidalgo JA, Blanch, S, Martinez, N, Murillo, L, Gomez-Pardo, P, Lopez-Gonzalez, A, Amillano, K, Canes, J, Galvan, P, Gonzalez-Farre, B, Gonzalez, X, Villagrasa, P, Ciruelos, E, Prat, A (2019).

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.

BREAST CANCER RESEARCH. Article. 21(1):108-108.
[doi:10.1186/s13058-019-1195-z]
Huober, J, Holmes, E, Baselga, J, de Azambuja, E, Untch, M, Fumagalli, D, Sarp, S, Lang, I, Smith, I, Boyle, F, Xu, BH, Lecocq, C, Wildiers, H, Jouannaud, C, Hackman, J, Dasappa, L, Ciruelos, E, Toral Pena JC, Adamchuk, H, Hickish, T, de la Pena, L, Jackisch, C, Gelber, RD, Piccart-Gebhart, M, Di Cosimo, S (2019).

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

EUROPEAN JOURNAL OF CANCER. Article. 118:169-177.
[doi:10.1016/j.ejca.2019.04.038]
Saura, C, Hlauschek, D, Oliveira, M, Zardavas, D, Jallitsch-Halper, A, de la Peña L, Nuciforo, P, Ballestrero, A, Dubsky, P, Lombard, JM, Vuylsteke, P, Castaneda, CA, Colleoni, M, Santos Borges G, Ciruelos, E, Fornier, M, Boer, K, Bardia, A, Wilson, TR, Stout, TJ, Hsu, JY, Shi, Y, Piccart, M, Gnant, M, Baselga, J, de Azambuja, E (2019).

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

LANCET ONCOLOGY. Article. 20(9):1226-1238.
[doi:10.1016/S1470-2045(19)30334-1]
Oliveira, M, Saura, C, Nuciforo, P, Calvo, I, Andersen, J, Passos-Coelho, JL, Gil, MG, Bermejo, B, Patt, DA, Ciruelos, E, de la Peña L, Xu, N, Wongchenko, M, Shi, Z, Singel, SM, Isakoff, SJ (2019).

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.

ANNALS OF ONCOLOGY. Article. 30(8):1289-1297.
[doi:10.1093/annonc/mdz177]
Ciruelos E, Alba E, López R, Lluch A, Martín M, Arroyo I, Navarro B, Carcedo D, Colomer R, Albanell J (2019).

Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval.

Oncotarget. Article. 10(42):4321-4332.
[doi:10.18632/oncotarget.27039]
Curigliano, G, Burstein, HJ, Winer, EP, Gnant, M, Dubsky, P, Loibl, S, Colleoni, M, Regan, MM, Piccart-Gebhart, M, Senn, HJ, Thurlimann, B, Andre, F, Baselga, J, Bergh, J, Bonnefoi, H, Brucker, SY, Cardoso, F, Carey, L, Ciruelos, E, Cuzick, J, Denkert, C, Di Leo, A, Ejlertsen, B, Francis, P, Galimberti, V, Garber, J, Gulluoglu, B, Goodwin, P, Harbeck, N, Hayes, DF, Huang, CS, Huober, J, Khaled, H, Jassem, J, Jiang, Z, Karlsson, P, Morrow, M, Orecchia, R, Osborne, KC, Pagani, O, Partridge, AH, Pritchard, K, Ro, J, Rutgers, EJT, Sedlmayer, F, Semiglazov, V, Shao, Z, Smith, I, Toi, M, Tutt, A, Viale, G, Watanabe, T, Whelan, TJ, Xu, B, St Gallen Int Expert Consensus (2019).

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (vol 28, pg 1700, 2017)

ANNALS OF ONCOLOGY. Correction. 30(7):1181-1181.
[doi:10.1093/annonc/mdy537]
Prat, A, Brase, JC, Cheng, Y, Nuciforo, P, Pare, L, Pascual, T, Martinez, D, Galvan, P, Vidal, M, Adamo, B, Hortobagyi, GN, Baselga, J, Ciruelos, E (2019).

Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.

ONCOLOGIST. Article. 24(7):893-900.
[doi:10.1634/theoncologist.2018-0407]
Ciruelos E, Pérez-García JM, Gavilá J, Rodríguez A, de la Haba-Rodriguez J (2019).

Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept.

CLINICAL DRUG INVESTIGATION. Review. 39(7):595-606.
[doi:10.1007/s40261-019-00790-9]
Lago, V, Fotopoulou, C, Chiantera, V, Minig, L, Gil-Moreno, A, Cascales-Campos, PA, Jurado, M, Tejerizo, A, Padilla-Iserte, P, Malune, ME, Di Donna, MC, Marina, T, Sanchez-Iglesias, JL, Olloqui, A, Garcia-Granero, A, Matute, L, Fornes, V, Domingo, S (2019).

Risk factors for anastomotic leakage after colorectal resection in ovarian cancer surgery: A multi-centre study.

GYNECOLOGIC ONCOLOGY. Article. 153(3):549-554.
[doi:10.1016/j.ygyno.2019.03.241]
Méndez-Líter JA, Tundidor, I, Nieto-Dominguez, M, de Toro, BF, González Santana A, de Eugenio, LI, Prieto, A, Asensio, JL, Cañada FJ, Sanchez, C, Martinez, MJ (2019).

Transglycosylation products generated by Talaromyces amestolkiae GH3 ß-glucosidases: effect of hydroxytyrosol, vanillin and its glucosides on breast cancer cells.

MICROBIAL CELL FACTORIES. Article. 18(1):97-97.
[doi:10.1186/s12934-019-1147-4]
Andre, F, Ciruelos, E, Rubovszky, G, Campone, M, Loibl, S, Rugo, HS, Iwata, H, Conte, P, Mayer, IA, Kaufman, B, Yamashita, T, Lu, YS, Inoue, K, Takahashi, M, Papai, Z, Longin, AS, Mills, D, Wilke, C, Hirawat, S, Juric, D, SOLAR-1 Study Group (2019).

Alpelisib for PIK3CA -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

NEW ENGLAND JOURNAL OF MEDICINE. Article. 380(20):1929-1940.
[doi:10.1056/NEJMoa1813904]
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D (2019).

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

ANNALS OF ONCOLOGY. Article. 30(5):766-773.
[doi:10.1093/annonc/mdz061]
Sanchez-Rovira, P, Zamora, P, Salvador-Bofill, J, Morales, S, Martinez-Janez, N, Martinez-de-Duenas, E, Lluch, A, Illarramendi, JJ, Gomez-Pardo, P, Gavilá Gregori J, Garcia-Palomo, A, Garcia-Mata, J, Fernandez, Y, del Barco, S, de Juan, A, Ciruelos, E, Chacon, JI, Calvo, L, Barnadas, A, Albanell, J (2019).

Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists.

Journal Of Drug Assessment. Article. 8(1):62-69.
[doi:10.1080/21556660.2019.1604375]
Manso, L, Moreno Anton F, Izarzugaza Peron Y, Delgado Mingorance JI, Borrega Garcia P, Echarri Gonzalez MJ, Martinez-Janez, N, Lopez-Gonzalez, A, Olier Garate C, Ballesteros Garcia A, Chacon Lopez-Muniz I, Ciruelos Gil E, Garcia-Saenz, JA, Paz-Ares, L (2019).

Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study

Breast Journal. Article. 25(2):219-225.
[doi:10.1111/tbj.13199]
Blasco-Benito, S, Moreno, E, Seijo-Vila, M, Tundidor, I, Andradas, C, Caffarel, MM, Caro-Villalobos, M, Uriguen, L, Diez-Alarcia, R, Moreno-Bueno, G, Hernandez, L, Manso, L, Homar-Ruano, P, McCormick, PJ, Bibic, L, Bernado-Morales, C, Arribas, J, Canals, M, Casado, V, Canela, EI, Guzman, M, Perez-Gomez, E, Sanchez, C (2019).

Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. Article. 116(9):3863-3872.
[doi:10.1073/pnas.1815034116]
Gonzalez-Rincon, J, Mendez, M, Gomez, S, Garcia, JF, Martin, P, Bellas, C, Pedrosa, L, Rodriguez-Pinilla, SM, Camacho, FI, Quero, C, Perez-Callejo, D, Rueda, A, Llanos, M, Gomez-Codina, J, Piris, MA, Montes-Moreno, S, Barcena, C, Rodriguez-Abreu, D, Menarguez, J, De la Cruz-Merino, L, Monsalvo, S, Parejo, C, Royuela, A, Kwee, I, Cascione, L, Arribas, A, Bertoni, F, Mollejo, M, Provencio, M, Sanchez-Beato, M (2019).

Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

PLOS ONE. Article. 14(2).
[doi:10.1371/journal.pone.0212813]
Page, A, Ortega, A, Alameda, JP, Navarro, M, Paramio, JM, Saiz-Pardo, M, Almeida, EI, Hernandez, P, Fernandez-Acenero, MJ, Garcia-Fernandez, RA, Casanova, ML (2019).

IKKa Promotes the Progression and Metastasis of Non-Small Cell Lung Cancer Independently of its Subcellular Localization.

Computational and Structural Biotechnology Journal. Article. 17:251-262.
[doi:10.1016/j.csbj.2019.02.003]
Cazzaniga ME, Ciruelos E, Fabi A, Garcia-Saenz J, Lindman H, Mavroudis D, Schem C, Steger G, Timotheadou E, Zaman K, Torri V, MACBETH Group (2019).

Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project.

CANCER CHEMOTHERAPY AND PHARMACOLOGY. Article. 83(2):301-318.
[doi:10.1007/s00280-018-3717-2]
Perez-Fidalgo, JA, Iglesias, M, Bohn, U, Calvo E, Garcia, Y, Guerra, E, Manso, L, Santaballa, A, Gonzalez-Martin, A (2019).

GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer

Future Science Oa. Article. 5(2).
[doi:10.4155/fsoa-2018-0107]
Cristofanilli, M, Pierga, JY, Reuben, J, Rademaker, A, Davis, AA, Peeters, DJ, Fehm, T, Nole, F, Gisbert-Criado, R, Mavroudis, D, Grisanti, S, Giuliano, M, Garcia-Saenz, JA, Stebbing, J, Caldas, C, Gazzaniga, P, Manso, L, Zamarchi, R, de Lascoiti, AF, de Mattos-Arruda, L, Ignatiadis, M, Cabel, L, van Laere, SJ, Meier-Stiegen, F, Sandri, MT, Vidal-Martinez, J, Politaki, E, Consoli, F, Generali, D, Cappelletti, MR, Diaz-Rubio, E, Krell, J, Dawson, SJ, Raimondi, C, Rutten, A, Janni, W, Munzone, E, Caranana, V, Agelaki, S, Almici, C, Dirix, L, Solomayer, EF, Zorzino, L, Darrigues, L, Reis, JS, Gerratana, L, Michiels, S, Bidard, FC, Pantel, K (2019).

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. Review. 134:39-45.
[doi:10.1016/j.critrevonc.2018.12.004]
Rojas, LK, Trilla-Fuertesr, L, Gamez-Pozo, A, Chiva, C, Sepulveda, J, Manso, L, Prado-Vazquez, G, Zapater-Moros, A, Lopez-Vacas, R, Ferrer-Gomez, M, Mendiola, C, Espinosa, E, Sabido, E, Ciruelos, E, Vara JAF (2019).

Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer

Ecancermedicalscience. Article. 13:891-891.
[doi:10.3332/ecancer.2019.891]
Alameda, JP, Ramirez, A, Garcia-Fernandez, RA, Navarro, M, Page, A, Segovia, JC, Sanchez, R, Suarez-Cabrera, C, Paramio, JM, Bravo, A, Fernandez-Acenero, MJ, Casanova, ML (2019).

Premature aging and cancer development in transgenic mice lacking functional CYLD

Aging-Us. Article. 11(1):127-159.
[doi:10.18632/aging.101732]
Gavila, J, Oliveira, M, Pascual, T, Perez-Garcia, J, Gonzalez, X, Canes, J, Pare, L, Calvo, I, Ciruelos, E, Munoz, M, Virizuela, JA, Ruiz, I, Andres, R, Perello, A, Martinez, J, Morales, S, Marin-Aguilera, M, Martinez, D, Quero, JC, Llombart-Cussac, A, Prat, A (2019).

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

BMC MEDICINE. Article. 17(1):8-8.
[doi:10.1186/s12916-018-1233-1]
Ayala de la Peña F, Andrés R, Garcia-Sáenz JA, Manso L, Margelí M, Dalmau E, Pernas S, Prat A, Servitja S, Ciruelos E (2019).

SEOM clinical guidelines in early stage breast cancer (2018)

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 21(1):18-30.
[doi:10.1007/s12094-018-1973-6]

2018

Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S, EORTC, MRC CHORUS study investigators (2018).

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

LANCET ONCOLOGY. Article. 19(12):1680-1687.
[doi:10.1016/S1470-2045(18)30566-7]
Blancas, I, Fontanillas, M, Conde, V, Lao, J, Martinez, E, Sotelo, MJ, Jaen, A, Bayo, JL, Carabantes, F, Illarramendi, JJ, Gordon, MM, Cruz, J, Garcia-Palomo, A, Mendiola, C, Perez-Ruiz, E, Bofill, JS, Baena-Canada, JM, Janez, NM, Esquerdo, G, Ruiz-Borrego, M (2018).

Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice (vol 20, pg 862, 2018)

CLINICAL & TRANSLATIONAL ONCOLOGY. Correction. 20(12):1631-1632.
[doi:10.1007/s12094-018-1956-7]
Blasco-Benito, S, Seijo-Vila, M, Caro-Villalobos, M, Tundidor, I, Andradas, C, Garcia-Taboada, E, Wade, J, Smith, S, Guzman, M, Perez-Gomez, E, Gordon, M, Sanchez, C (2018).

Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer

BIOCHEMICAL PHARMACOLOGY. Article. 157:285-293.
[doi:10.1016/j.bcp.2018.06.025]
Minig, L, Cabrera, S, Oliver, R, Couso, A, Rubio, MJ, Iacoponi, S, Martin-Salamanca, MB, Carballo-Rastrilla, S, Cadenas-Rebollo, JM, Garcia-Garcia, A, Gil-Ibanez, B, Juan-Fita, MJ, Patrono, MG (2018).

Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 20(10):1337-1344.
[doi:10.1007/s12094-018-1865-9]
Jiménez-Heffernan JA, Bárcena C, Muñoz-Hernández P (2018).

Cytological features of breast peri-implant papillary synovial metaplasia

DIAGNOSTIC CYTOPATHOLOGY. Article. 46(9):769-771.
[doi:10.1002/dc.23947]
Vergote, I, von Moos, R, Manso, L, Van Nieuwenhuysen, E, Concin, N, Sessa, C (2018).

Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study

GYNECOLOGIC ONCOLOGY. Article. 150(3):471-477.
[doi:10.1016/j.ygyno.2018.07.018]
Zagorac, I, Fernandez-Gaitero, S, Penning, R, Post, H, Bueno, MJ, Mouron, S, Manso, L, Morente, MM, Alonso, S, Serra, V, Munoz, J, Gomez-Lopez, G, Lopez-Acosta, JF, Jimenez-Renard, V, Gris-Oliver, A, Al-Shahrour, F, Pineiro-Yanez, E, Montoya-Suarez, JL, Apala, JV, Moreno-Torres, A, Colomer, R, Dopazo, A, Heck AJR, Altelaar, M, Quintela-Fandino, M (2018).

In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer

NATURE COMMUNICATIONS. Article. 9(1):3501-3501.
[doi:10.1038/s41467-018-05742-z]
Pernaut, C, Lopez, F, Ciruelos, E (2018).

Standard Neoadjuvant Treatment in Early/Locally Advanced Breast Cancer

Breast Care. Review. 13(4):244-249.
[doi:10.1159/000491759]
Colomer R, Aranda-Lopez I, Albanell J, Garcia-Caballero T, Ciruelos E, Lopez-Garcia MA, Cortes J, Rojo F, Martin M, Palacios-Calvo J (2018).

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology (vol 20, pg 815, 2018)

CLINICAL & TRANSLATIONAL ONCOLOGY. Correction. 20(8):1093-1095.
[doi:10.1007/s12094-018-1909-1]
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I, Gomez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM, SOFT and TEXT Investigators and the International Breast Cancer Study Group (2018).

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

NEW ENGLAND JOURNAL OF MEDICINE. Article. 379(2):122-137.
[doi:10.1056/NEJMoa1803164]
Blancas, I, Fontanillas, M, Conde, V, Lao, J, Martinez, E, Sotelo, MJ, Jaen, A, Bayo, JL, Carabantes, F, Illarramendi, JJ, Gordon, MM, Cruz, J, Garcia-Palomo, A, Mendiola, C, Perez-Ruiz, E, Bofill, JS, Baena-Canada, JM, Janez, NM, Esquerdo, G, Ruiz-Borrego, M (2018).

Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 20(7):862-869.
[doi:10.1007/s12094-017-1797-9]
Colomer, R, Aranda-Lopez, I, Albanell, J, Garcia-Caballero, T, Ciruelos, E, Lopez-Garcia, MA, Cortes, J, Rojo, F, Martin, M, Palacios-Calvo, J (2018).

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

CLINICAL & TRANSLATIONAL ONCOLOGY. Review. 20(7):815-826.
[doi:10.1007/s12094-017-1800-5]
Pernas, S, Martin, M, Kaufman, PA, Gil-Martin, M, Gomez Pardo P, Lopez-Tarruella, S, Manso, L, Ciruelos, E, Perez-Fidalgo, JA, Hernando, C, Ademuyiwa, FO, Weilbaecher, K, Mayer, I, Pluard, TJ, Martinez Garcia M, Vahdat, L, Perez-Garcia, J, Wach, A, Barker, D, Fung, S, Romagnoli, B, Cortes, J (2018).

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

LANCET ONCOLOGY. Article. 19(6):812-824.
[doi:10.1016/S1470-2045(18)30147-5]
Ciruelos, E, Vidal, M, Martínez de Dueñas E, Martinez-Janez, N, Fernandez, Y, Garcia-Saenz, J, Murillo, L, Carabantes, F, Beliera, A, Fonseca, R, Gavila, J (2018).

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 20(6):753-760.
[doi:10.1007/s12094-017-1784-1]
Carretero-Gonzalez, A, Otero, I, Carril-Ajuria, L, de Velasco, G, Manso, L (2018).

Exosomes: Definition, Role in Tumor Development and Clinical Implications

CANCER MICROENVIRONMENT. Review. 11(1):13-21.
[doi:10.1007/s12307-018-0211-7]
Selle, F, Colombo, N, Korach, J, Mendiola, C, Cardona, A, Ghazi, Y, Oza, AM (2018).

Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Article. 28(4):729-737.
[doi:10.1097/IGC.0000000000001221]
Cala, MP, Agullo-Ortuno, MT, Prieto-Garcia, E, Gonzalez-Riano, C, Parrilla-Rubio, L, Barbas, C, Diaz-Garcia, CV, Garcia, A, Pernaut, C, Adeva, J, Riesco, MC, Ruperez, FJ, Lopez-Martin, JA (2018).

Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE. Article. 9(2):348-357.
[doi:10.1002/jcsm.12270]
Prat, A, Brase, JC, Cheng, Y, Nuciforo, P, Pare, L, Pascual, T, Martinez, D, Galvan, P, Vidal, M, Adamo, B, Hortobagyi, G, Baselga, J, Ciruelos, E (2018).

PAM50 intrinsic subtype in hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial

EUROPEAN JOURNAL OF CANCER. Meeting Abstract. 92:117-117.
[doi:10.1016/S0959-8049(18)30574-4]
Kaufman, PA, Pernas, S, Martin, M, Gil-Martin, M, Pardo, PG, Sara, LT, Manso, L, Ciruelos, E, Perez-Fidalgo, JA, Hernando, C, Ademuyiwa, FO, Weilbaecher, K, Mayer, I, Pluard, TJ, Garcia, MM, Vahdat, L, Wach, A, Barker, D, Romagnoli, B, Cortes, J (2018).

Balixafortide (a CXCR4 antagonist) plus eribulin in HER2-negative metastatic breast cancer (MBC): A Phase I open-label trial

EUROPEAN JOURNAL OF CANCER. Meeting Abstract. 92:117-118.
Oskay-Özcelik G, Alavi S, Richter R, Keller M, Cecere SC, Cormio G, Joly F, Kurtz JE, du Bois A, Maciejewski M, Jedryka M, Vergote I, Van Nieuwenhuysen E, Casado A, Mendiola C, Achimas-Cadariu P, Vlad C, Reimer D, Zeimet AG, Friedlander M, Sehouli J (2018).

Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries.

ANNALS OF ONCOLOGY. Article. 29(4):910-916.
[doi:10.1093/annonc/mdy037]
Brandariz L, Arriba M, García JL, Cano JM, Rueda D, Rubio E, Rodríguez Y, Pérez J, Vivas A, Sánchez C, Tapial S, Pena L, García-Arranz M, García-Olmo D, Urioste M, González-Sarmiento R, Perea J (2018).

Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location.

Oncotarget. Article. 9(20):15302-15311.
[doi:10.18632/oncotarget.24502]
Garrido, ML, Morago, AJ, Rovira, PS, Olarte, PE, Sanchez, CP, Sanchez, LM (2018).

Experience with eribulin in the treatment of elderly women with metastatic breast cancer:case studies

FUTURE ONCOLOGY. Article. 14(7):21-27.
[doi:10.2217/fon-2017-0357]
de Azambuja, E, Saura, C, Nuciforo, P, Frantal, S, Oliveira, M, Zardavas, D, Jallitsch-Halper, A, de la Pena, L, Dubsky, P, Lombard, JM, Vuylsteke, P, Altamirano, CC, Sanchez, C, Ballestrero, A, Colleoni, M, Borges, GS, Ciruelos, E, Bardia, A, Fornier, M, Boer, K, Wilson, TR, Stout, TJ, Hsu, JY, Shi, Y, Piccart, M, Baselga, J, Gnant, M (2018).

Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer

CANCER RESEARCH. Meeting Abstract. 78(4).
Cortes, A, Apala, JV, Malon, D, Guerra, J, Gion-Cortes, M, Manso, L, Hornedo, J, Gonzalez-Cortijo, L, Mouron, S, Quintela-Fandino, M (2018).

CNIO-BR-009 trial: Targeting mitochondrial metabolism with ME-344 in breast cancer upon bevacizumab-induced vascular normalization: A phase 0 randomized clinical trial

CANCER RESEARCH. Meeting Abstract. 78(4).
Gavila, J, Oliveira, M, Pascual, T, Perez, J, Canes, J, Gonzalez, X, Pare, L, Calvo, I, Ciruelos, E, Munoz, M, Virizuela, JA, Ruiz, I, Andres, R, Perello, A, Martinez, J, Morales, S, Marin, M, Martinez, D, Quero, JC, Llombart-Cussac, A, Prat, A (2018).

Association of intrinsic subtype and immune genes with pathological complete response in the OPTIHER-HEART phase II clinical trial following neoadjuvant trastuzumab/pertuzumab-based chemotherapy in HER2-positive breast cancer

CANCER RESEARCH. Meeting Abstract. 78(4).
Nuciforo, P, Holgado, E, Llombart, A, Fasani, R, Pare, L, Pascual, T, Oliveira, M, Martinez, N, Bermejo, B, Vidal, M, Pernas, S, Lopez, R, Munoz, M, Garau, I, Manso, L, Alarcon, J, Martinez, E, Villagrasa, P, Cortes, J, Prat, A (2018).

A predictive model of pathological response following dual HER2 blockade-only based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer

CANCER RESEARCH. Meeting Abstract. 78(4).
Gil-Gil, M, Bellet, M, Morales, S, Barnadas, A, Manso, L, Ruiz, IM, Azaro, A, Gil, EC, Martinez, EG, Marinez, N, Mele, M, Soler, T, Villagrasa, P, Pernas, S (2018).

SOLTI-0702 CAPRICE: Final results of a phase II study of pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as neoadjuvant chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: 5-year overall survival disease free survival and late cardiac safety

CANCER RESEARCH. Meeting Abstract. 78(4).
Ciruelos, E, Villagrasa, P, Pare, L, Oliveira, M, de la Pena, L, Pernas, S, Cortes, J, Soberino, J, Adamo, B, Vazquez, S, Martinez, N, Perello, A, Bermejo, B, Martinez, E, Garau, I, Mele, M, Morales, S, Galvan, P, Pascual, T, Nuciforo, P, Gonzalez, X, Prat, A (2018).

PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial

CANCER RESEARCH. Meeting Abstract. 78(4).
Smyth, LM, Oliveira, M, Ciruelos, E, Tamura, K, El-Khoueiry, A, Mita, A, You, B, Renouf, DJ, Sablin, MP, Lluch, A, Mayer, IA, Bando, H, Yamashita, H, Ambrose, H, de Bruin, E, Carr, TH, Corcoran, C, Foxley, A, Lindemann, JPO, Maudsley, R, Pass, M, Rutkowski, A, Schiavon, G, Banerji, U, Scaltriti, M, Taylor, BS, Chandarlapaty, S, Baselga, J, Hyman, DM (2018).

AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer

CANCER RESEARCH. Meeting Abstract. 78(4).
Nuciforo, P, Pascual, T, Cortes, J, Llombart-Cussac, A, Fasani, R, Pare, L, Oliveira, M, Galvan, P, Martinez, N, Bermejo, B, Vidal, M, Pernas, S, Lopez, R, Muñoz M, Garau, I, Manso, L, Alarcon, J, Martinez, E, Rodrik-Outmezguine, V, Brase, JC, Villagrasa, P, Prat, A, Holgado, E (2018).

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

ANNALS OF ONCOLOGY. Article. 29(1):170-177.
[doi:10.1093/annonc/mdx647]
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, Panel Members of the St Gallen International Expert Consensus on the Primary The, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B (2018).

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

ANNALS OF ONCOLOGY. Letter. 29(1):281-282.
[doi:10.1093/annonc/mdx543]
Di Leo, A, Johnston, S, Lee, KS, Ciruelos, E, Lønning PE, Janni, W, O'Regan, R, Mouret-Reynier, MA, Kalev, D, Egle, D, Csoszi, T, Bordonaro, R, Decker, T, Tjan-Heijnen VCG, Blau, S, Schirone, A, Weber, D, El-Hashimy, M, Dharan, B, Sellami, D, Bachelot, T (2018).

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

LANCET ONCOLOGY. Article. 19(1):87-100.
[doi:10.1016/S1470-2045(17)30688-5]
Leo, AD, Toi, M, Campone, M, Sohn, JH, Shimon, SP, Huober, J, Park, IH, Tredan, O, Chen, SC, Manso, L, Freedman, O, Jaliffe, GG, Forrester, TD, Frenzel, M, Barriga, S, Smith, IC, Bourayou, N, Goetz, MP (2018).

MONARCH 3: Abemaciclib as Initial Therapy for Patients with HR+/HER2-Advanced Breast Cancer

ONCOLOGY RESEARCH AND TREATMENT. Meeting Abstract. 41:5-5.
Manso, L, Sanchez-Munoz, A, Calvo, I, Izarzugaza, Y, Plata, J, Rodriguez, C (2018).

Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer

Breast Care. Review. 13(4):277-283.
[doi:10.1159/000488794]
Redondo, A, Ramos Vazquez M, Manso, L, Gil, MJG, Garau Llinas I, Garcia-Garre, E, Rodriguez, CA, Chacon, JI, Lopez-Vivanco, G (2018).

Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study

ONCOTARGETS AND THERAPY. Article. 11:5845-5852.
[doi:10.2147/OTT.S170303]

2017

Page A, Navarro M, Suárez-Cabrera C, Bravo A, Ramirez A (2017).

Context-Dependent Role of IKKß in Cancer.

Genes. Article. 8(12).
[doi:10.3390/genes8120376]
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A (2017).

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

JOURNAL OF CLINICAL ONCOLOGY. Article. 35(32):3638-3646.
[doi:10.1200/JCO.2017.75.6155]
Díaz-Alonso J, de Salas-Quiroga A, Paraíso-Luna J, García-Rincón D, Garcez PP, Parsons M, Andradas C, Sánchez C, Guillemot F, Guzmán M, Galve-Roperh I (2017).

Loss of Cannabinoid CB1 Receptors Induces Cortical Migration; Malformations and Increases Seizure Susceptibility

CEREBRAL CORTEX. Article. 27(11):5303-5317.
[doi:10.1093/cercor/bhw309]
Oliver-Pérez MLR, Bravo Violeta V, Legorburu Alonso B, Betancor Pérez D, Bebia Conesa V, Jiménez López JS (2017).

Incidence of Anal Dysplasia in a Population of High-Risk Women:; Observations at a Cervical Pathology Unit

JOURNAL OF LOWER GENITAL TRACT DISEASE. Article. 21(4):329-335.
[doi:10.1097/LGT.0000000000000328]
Pont LP, Marcelli S, Robustillo M, Song D, Grandes D, Martin M, Iglesias I, Aso J, Laloumet I, Díaz AJ (2017).

Immediate Breast Reconstruction with Abdominal Free Flap and Adjuvant; Radiotherapy: Evaluation of Quality of Life and Outcomes

PLASTIC AND RECONSTRUCTIVE SURGERY. Article. 140(4):681-690.
[doi:10.1097/PRS.0000000000003664]
Page A, Bravo A, Suarez-Cabrera C, Alameda JP, Casanova ML, Lorz C, Segrelles C, Segovia JC, Paramio JM, Navarro M, Ramirez A (2017).

IKK beta-Mediated Resistance to Skin Cancer Development Is; Ink4a/Arf-Dependent

MOLECULAR CANCER RESEARCH. Article. 15(9):1255-1264.
[doi:10.1158/1541-7786.MCR-17-0157]
Gamez-Pozo, A, Trilla-Fuertes, L, Berges-Soria, J, Selevsek, N, Lopez-Vacas, R, Diaz-Almiron, M, Nanni, P, Arevalillo, JM, Navarro, H, Grossmann, J, Moreno, FG, Rioja, RG, Prado-Vazquez, G, Zapater-Moros, A, Main, P, Feliu, J, del Prado, PM, Zamora, P, Ciruelos, E, Espinosa, E, Vara, JAF (2017).

Functional proteomics outlines the complexity of breast cancer molecular; subtypes

SCIENTIFIC REPORTS. Article. 7(1):10100-10100.
[doi:10.1038/s41598-017-10493-w]
Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, St. Gallen International Expert Consensus on the Primary Therapy of Early Breast, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B (2017).

De-escalating and escalating treatments for early-stage breast cancer:; the St. Gallen International Expert Consensus Conference on the Primary; Therapy of Early Breast Cancer 2017

ANNALS OF ONCOLOGY. Article. 28(8):1700-1712.
[doi:10.1093/annonc/mdx308]
Villalaín-González C, Tejerizo-García Á, Lopez-Garcia P, López-González G, Oliver-Perez MR, Jiménez-López JS (2017).

Vaginal metastasis as the initial presentation of leiomyosarcoma: a case; report

BMC CANCER. Article. 17(1):503-503.
[doi:10.1186/s12885-017-3484-1]
Pascual, T, Apellaniz-Ruiz, M, Pernaut, C, Cueto-Felgueroso, C, Villalba, P, Alvarez, C, Manso, L, Inglada-Perez, L, Robledo, M, Rodriguez-Antona, C, Ciruelos, E (2017).

Polymorphisms associated with everolimus pharmacokinetics, toxicity and; survival in metastatic breast cancer

PLOS ONE. Article. 12(7).
[doi:10.1371/journal.pone.0180192]
Simón E, Tejerizo Á, Muñoz JL, Álvarez C, Marqueta L, Jiménez JS (2017).

Conservative management in ureteric hydronephrosis due to deep; endometriosis: Could the levonorgestrel-intrauterine device be an; option?

JOURNAL OF OBSTETRICS AND GYNAECOLOGY. Article. 37(5):639-644.
[doi:10.1080/01443615.2017.1286467]
Gámez-Pozo A, Trilla-Fuertes L, Prado-Vázquez G, Chiva C, López-Vacas R, Nanni P, Berges-Soria J, Grossmann J, Díaz-Almirón M, Ciruelos E, Sabidó E, Espinosa E, Fresno Vara JÁ (2017).

Prediction of adjuvant chemotherapy response in triple negative breast; cancer with discovery and targeted proteomics

PLOS ONE. Article. 12(6).
[doi:10.1371/journal.pone.0178296]
Rynne-Vidal A, Au-Yeung CL, Jiménez-Heffernan JA, Pérez-Lozano ML, Cremades-Jimeno L, Bárcena C, Cristóbal-García I, Fernández-Chacón C, Yeung TL, Mok SC, Sandoval P, López-Cabrera M (2017).

Mesothelial-to-mesenchymal transition as a possible therapeutic target; in peritoneal metastasis of ovarian cancer

JOURNAL OF PATHOLOGY. Article. 242(2):140-151.
[doi:10.1002/path.4889]
Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS (2017).

A phase II study of combined ridaforolimus and dalotuzumab compared with; exemestane in patients with estrogen receptor-positive breast cancer

BREAST CANCER RESEARCH AND TREATMENT. Article. 163(3):535-544.
[doi:10.1007/s10549-017-4199-3]
Jiménez-Heffernan JA, Freih Fraih A, Álvarez F, Bárcena C, Corbacho C (2017).

Cytologic Features of Pleomorphic Xanthoastrocytoma, WHO Grade II. A; Comparative Study with Glioblastoma

DIAGNOSTIC CYTOPATHOLOGY. Article. 45(4):339-344.
[doi:10.1002/dc.23660]
Alkatout I, Hübner F, Wenners A, Hedderich J, Wiedermann M, Sánchez C, Röcken C, Mathiak M, Maass N, Klapper W (2017).

In situ localization of tumor cells associated with the; epithelial-mesenchymal transition marker Snail and the prognostic impact; of lymphocytes in the tumor microenvironment in invasive ductal breast; cancer

EXPERIMENTAL AND MOLECULAR PATHOLOGY. Article. 102(2):268-275.
[doi:10.1016/j.yexmp.2017.02.013]
Fernandez-Martinez A, Pascual T, Perrone G, Morales S, de la Haba J, González-Rivera M, Galván P, Zalfa F, Amato M, Gonzalez L, Prats M, Rojo F, Manso L, Paré L, Alonso I, Albanell J, Vivancos A, González A, Matito J, González S, Fernandez P, Adamo B, Muñoz M, Viladot M, Font C, Aya F, Vidal M, Caballero R, Carrasco E, Altomare V, Tonini G, Prat A, Martin M (2017).

Limitations in predicting PAM50 intrinsic subtype and risk of relapse; score with Ki67 in estrogen receptor-positive HER2-negative breast; cancer

Oncotarget. Article. 8(13):21930-21937.
[doi:10.18632/oncotarget.15748]
Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA (2017).

Critically short telomeres and toxicity of chemotherapy in early breast; cancer

Oncotarget. Article. 8(13):21472-21482.
[doi:10.18632/oncotarget.15592]
Page A, Navarro M, Suarez-Cabrera C, Alameda JP, Casanova ML, Paramio JM, Bravo A, Ramirez A (2017).

Protective role of p53 in skin cancer: Carcinogenesis studies in mice; lacking epidermal p53 (vol 7, pg 20902, 2016)

Oncotarget. Correction. 8(13):22304-22304.
[doi:10.18632/oncotarget.16592]
Suárez-Cabrera C, Quintana RM, Bravo A, Casanova ML, Page A, Alameda JP, Paramio JM, Maroto A, Salamanca J, Dupuy AJ, Ramírez A, Navarro M (2017).

A Transposon-based Analysis Reveals RASA1 Is Involved in Triple-Negative Breast Cancer

CANCER RESEARCH. Article. 77(6):1357-1368.
[doi:10.1158/0008-5472.CAN-16-1586]
Di Leo, A., Lee, K. Seok, Ciruelos, E., Lonning, P., Janni, W., O'Regan, R., Reynier, M-A Mouret, Kalev, D., Egle, D., Csoszi, T., Bordonaro, R., Decker, T., Tjan-Heijnen, V. C., Blau, S., Schirone, A., Weber, D., El-Hashimy, M., Dharan, B., Sellami, D., Bachelot, T. (2017).

BELLE-3: A phase III study of buparlisib plus fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-S4-07]
Pascual, T., Gamez-Pozo, A., Camara-Jurado, M., Manso, L. M., Perez-Campos, A., Trilla, L., Fresno-Vara, J. A., Ciruelos, E. M. (2017).

Differential expression of microRNAs (miRNAs) in HER2 negative breast cancer (BC)

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P4-07-09]
Martin, M., Kahan, Z., Carrasco, E., Bartlett, C. H., Casas, M., Gil-Gil, M., Munoz, M., Ciruelos, E. M., Ruiz-Borrego, M., Margeli, M., Anton, A., Bermejo, B., Morales, S., Gal-Yam, E., Koehler, M., Garcia-Saenz, J. A., de la Haba, J., Chacon, I., Zielinski, C. (2017).

Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. ``The PEARL study'' (GEICAM/2013-02)

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-OT2-01-06]
Manso Sanchez, L., Moreno Anton, F., Izarzugaza Peron, Y., Delgado Mingorance, I., Borrega Garcia, P., Echarri Gonzalez, M. J., Martinez Janez, N., Lopez Gonzalez, A., Olier Garate, C., Ballesteros Garcia, A., Chacon Lopez-Muniz, I., Ciruelos Gil, E. M., Garcia Saenz, J. A., Paz-Ares Rodriguez, L. (2017).

High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P6-07-21]
Gavila, J., Perez-Garcia, J., Calvo, I., Ciruelos, E., Munoz, M., Virizuela, J. A., Ruiz, I., Andres, R., Morales, S., Perello, A., Sanchez, P., Garcia-Saenz, J. A., Quero Guillen, J. C., Gonzalez-Santiago, S., Garau Llinas, I., Gonzalez-Martin, A., Sanchez de Ibarguen, B. Cantos, Zaragoza, K., de la Pena, L., Llombart-Cussac, A., Oliveira, M. (2017).

Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+breast cancer - Final results of the SOLTI OPTI-HER HEART study

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P4-21-05]
Bachelot, T., Puglisi, F., Ciruelos, E., Peretz-Yablonski, T., Schneeweiss, A., Easton, V., Lindegger, N., Restuccia, E., Miles, D. (2017).

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE)

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P4-21-04]
Colomer, R., Ciruelos, E., De la Haba, J., Martin, M., De Salas-Cansado, M., Munoz-Molina, B., Albanell, J. (2017).

Estimating costs of relapsing HER2+breast cancer in Spain

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P3-12-05]
Ciruelos, E. M., Montano, A., Rodriguez, C. A., Gonzalez-Flores, E., Lluch, A., Garrigos, L., Quiroga, V., Anton, A., Malon, D., Chacon, J. I., Velasco, M., Gonzalez-Cortijo, L., Jolis, L., Pascual, T., Amigo, Y., Casas, M., Camara, M. C., Carrasco, E., Casas, A. (2017).

Phase III trial to evaluate patient's preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07)

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P4-21-16]
Andre, F., Kaufman, B., Juric, D., Ciruelos, E. M., Iwata, H., Mayer, I. A., Rugo, H. S., Conte, P., Liobl, S., Rubovszky, G., Inoue, K., Tesch, H., Lu, Y-S, Ryvo, L., Longin, A-S, Mills, D., Wilke, C., Germa, C., Campone, M. (2017).

SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-OT2-01-04]
Adamo, B., Vidal, M., Gomez Pardo, P., Zaragoza, K., Ciruelos, E., Virizuela, J. A., Blanch Tormo, S., Perez-Fidalgo, J. A., Murillo, L., Lopez-Gonzalez, A., Amillano Parraga, K., Martinez Janez, N., Gonzalez Farre, X., Prat, A. (2017).

VENTANA (SOLTI-1501): Oral metronomic vinorelbine combined with endocrine therapy in Eluminal/HER2-negative early breast cancer: A window of opportunity trial

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-OT1-01-04]
Abanell, J., Ciruelos, E., De la Haba, J., Martin, M., Munoz-Molina, B., De Salas-Cansado, M., Colomer, R. (2017).

Cost-effectiveness analysis of adding neoadjuvant chemotherapy with pertuzumab, in patients with HER2+breast cancer in Spain

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P3-12-02]
Deurloo, R, Colombo, N, Mendiola, C, Selle, F, Korach, J, Oestergaard, MZ, Bylesjo, M, Urban, HJ, Ghazi, Y, Oza, A (2017).

Gene mutational analyses in 154 ovarian cancer (OC) samples from the; ROSiA study of front-line bevacizumab (BEV)-containing therapy for OC

ANNALS OF ONCOLOGY. Meeting Abstract. 28.
Di Leo, A, Toi, M, Campone, M, Sohn, J, Paluch-Shimon, S, Huober, J, Park, IH, Tredan, O, Chen, SC, Manso, L, Freedman, O, Jaliffe, GG, Forrester, T, Frenzel, M, Barriga, S, Smith, IC, Bourayou, N, Goetz, MP (2017).

MONARCH 3: Abemaciclib as initial therapy for patients with; HR+/HER2-advanced breast cancer

ANNALS OF ONCOLOGY. Meeting Abstract. 28.
Lopez-Martin, JA, Cala, M, Prieto-Garcia, E, Riano, CG, Diaz-Garcia, CV, Garcia, A, Marques, VP, Pascualena, FR, Garcia-Ruiz, I, Pernaut, C, Otero, I, Rubio, LP, Riesco, MC, Alfonso, JA, Barbas, C, Agullo-Ortuno, MT (2017).

Metabolomics in cancer cachexia

ANNALS OF ONCOLOGY. Meeting Abstract. 28.
Barcena, C, Rojas, K, Lema, L, Sanchez, LM, Rios, J, Garcia-Martin, R, Maroto, A, Rodriguez-Peralto, JL, Gil, EMC, Mendiola, DC, Paz-Ares, L (2017).

Tumor-infiltrating lymphocytes expression in stage IIIc/IV of high-grade; serous ovarian cancer: Variation with neoadjuvant chemotherapy and; prognostic value

ANNALS OF ONCOLOGY. Meeting Abstract. 28.
Adamo, B, Fidalgo, JAP, Ciruelos, E, Vidal, M, Blanch, S, Lopez, A, Pardo, PG, Murillo, L, Amillano, K, Janez, NM, Gonzalez, X, Canes, J, Prat, A (2017).

VENTANA (SOLTI-1501): Antiproliferative effect of the addition of oral; metronomic vinorelbine to endocrine therapy in luminal/HER2-negative; early breast cancer: A window of opportunity trial

ANNALS OF ONCOLOGY. Meeting Abstract. 28.

Quintana-Bertó R, Padilla-Iserte P, Gil-Moreno A, Oliver-Pérez R, Coronado PJ, Martín-Salamanca MB, Pantoja-Garrido M, Lorenzo C, Cazorla E, Gilabert-Estellés J, Sánchez L, Roldán-Rivas F, Díaz-Feijoo B, Rodríguez-Hernández JR, Marcos-Sanmartin J, Muruzábal JC, Cañada A, Domingo S ().

Oncological safety of hysteroscopy in endometrial cancer.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Article.
[doi:10.1136/ijgc-2022-003586]